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Abstract 
 
In the present diploma thesis we investigated a consanguineous Egyptian family with 
an autosomal recessive trait of temporal lobe epilepsy (TLE), myoclonus and tremor. 
Five of seven siblings in this family are affected. We employed multipoint linkage 
analysis to map the causative mutation within chromosome 1q31.3-q32.3 achieving 
a maximal LOD score of 3.6. This region encompasses 12.5 megabases (Mb) 
including 136 genes. For further investigation of the linked interval we selected two 
patients for EXOME sequencing. Within the linked region we identified a 
homozygous single base pair deletion (c.503_503delG) in the 6th exon of the 
CNTN2 gene leading to a frameshift within the coding region. As expected for a 
recessive disease, the mutation occurred in a homozygous state in the affected 
children and in a heterozygous state in the clinically healthy parents. CNTN2 is a 
glycosylphosphatidylinositol (GPI)-anchored neuronal membrane protein located in 
the juxtaparanode region of the axon and is responsible for the clustering of 
K+channels in the underlying axonal membrane.  
Previous studies report on CNTN2 knock out mice suffering from spontaneous 
seizures. Given the severity of the mutation and the proposed function of the gene, 
we consider this mutation as the most likely cause for the disease in this family. To 
find out whether mutations in this gene are contributors to clinical similar phenotypes 
we employed capillary sequencing of all 22 coding exons in 189 Caucasian patients 
with TLE or TLE associated with myoclonus. We detected seven rare missense 
variations in eight individuals. However, as all missense variations occurred 
throughout in a heterozygous state, their pathogenic significance remains 
questionable. In summary, we have identified a loss of function mutation in the 
CNTN2 gene in a family with recessive temporal lobe epilepsy syndrome. Future 
studies will reveal the significance of this gene in epilepsy in general.  
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Zusammenfassung 
 
In der vorliegenden Diplomarbeit untersuchten wir eine konsanguine ägyptische 
Familie, in der fünf von sieben Kindern an einer autosomal rezessiv vererbten 
Temporallappenepilepsie verbunden mit Myoklonien und Tremor erkrankt sind. In 
einer Mehrpunkt-Kopplungsanalyse (LOD 3.6) konnte die Kandidatenregion auf 
einen Bereich zwischen Chromosom 1q31.3-q32.3 eingegrenzt werden. Dieser 
Bereich umfasst 12.5 Millionen Basenpaare (Mb) und enthält 136 proteinkodierende 
Gene. Um die ursächliche Mutation zu finden führten wir bei zwei betroffenen 
Personen eine EXOM Sequenzierung durch.  
Innerhalb der Kandidationregion konnten wir eine homozygote Deletion einer 
Einzelbase (c.503_503delG) im Exon 6 des CNTN2 Gens identifizieren, welche zu 
einer Verschiebung des Leserasters führt. Wie erwartet, zeigte sich die Mutation in 
den betroffenen Familienmitgliedern in homozygoter Form und in den Eltern in 
heterozygoter Form. CNTN2 kodiert für ein neuronales Adhäsionsmolekül, das 
mittels eines Glycosylphosphatidylinositol (GPI)-Ankers mit der Neuronenmembran 
verbunden ist. Es ist in der juxtaparanodalen Region des Axons lokalisiert und 
verantwortlich für die Clusterbildung der K+ Kanäle in der darunterliegenden 
Axonmembran.  
In früheren Studien konnte gezeigt werden, dass CNTN2 defiziente Mäuse spontan 
zu Krampfanfällen neigen. Unter Berücksichtigung der postulierten Funktion des 
CNTN2 Proteins einerseits und der schweren Auswirkung der gefundenen Mutation 
auf dessen Struktur andererseits, erachten wir die Mutation als wahrscheinlich 
krankheitsverursachend in dieser Familie. Um Herauszufinden, ob Mutationen in 
diesem Gen auch bei klinisch ähnlichen Epilepsiesyndromen zur Erkrankung 
beitragen, sequenzierten wir alle 22 proteinkodierende Exone des Gens in 189 
kaukasischen Patienten mit entweder nur Temporallappenepilepsie oder 
Temporallappenepilepsie mit Myoklonien. Wir fanden sieben seltene missense 
Variationen in acht Patienten. Da jedoch alle Varianten ausschließlich in 
heterozygoter Form auftraten, muss die Frage nach deren Pathogenität offen bleiben. 
  XI 
Zusammengefasst lässt sich festhalten, dass wir eine homozygote Mutation im 
CNTN2 Gen, welche zu einem Funktionsverlust des Proteins führt, in einer 
ägyptischen Familie mit einem rezessiven Temporallappenepilepsiesyndrom 
gefunden haben. Welche Bedeutung dieses neue vielversprechende Kandidatengen 
für Epilepsie im Allgemeinen hat, müssen zukünftige Studien zeigen.  
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1 Introduction 
 
 
1.1 Definition and Epidemiology 
 
Epilepsy is one of the most common chronic neurological disorders in humans 
defined by the state of recurrent, spontaneous epileptic seizures (Blume et al., ILAE 
2001). Epileptic seizures, the main symptoms that subjects experience, arise from 
periodic neuronal cortical hyperexcitability and can be caused by multiple 
mechanisms. Epilepsy is a persistent epileptogenic abnormality of the cortical brain 
that is able to spontaneously generate paroxysmal activity (Engel, 2006). An epilepsy 
syndrome is a complex of signs and symptoms of epileptic conditions and additional 
clinical features which comprises a cluster of different seizure types (Engel et al., 
2001). 
In developed countries the incidence is about 50 cases per 100 000 persons per 
year (Sander and Shorvon, 1996). Incidence rates vary considerably with age. 
During the first years of life the incidence is very high, decreases in adolescence and 
increases again in the elderly (Sander et al., 1990). A more recent study of the 
epidemiology of epilepsy in Europe shows a prevalence between 4.5 -7.0 per 1000 
among all age groups estimating that approximately 6 of 1000 Europeans have 
active epilepsy, considering incomplete case identification (Forsgren et al., 2005). 
However, generation of precise epidemiological statistics for a disease like epilepsy 
which is characterized by heterogeneity is difficult.  
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1.2 Etiology 
 
Generally, epilepsies are classified into three major categories: (i) idiopathic epilepsy 
also termed as genetic epilepsy has no known cause. For this form hereditary factors 
are thought to play a dominant role in disease etiology. In case the genetic mutation 
is known, family members can be diagnosed by genetic testing. (ii) symptomatic 
(structural/metabolic) epilepsy is caused by a known or suspected associated deficit 
(e.g. trauma or tumours). The cause is a primary disease which is associated with the 
development of epilepsy. The third category, cryptogenic (iii) comprises all forms of 
epilepsy with a yet unknown underlying cause, which may be a genetic component or 
a yet undetected disease. 
Genetic defects may be some of the most important factors contributing to epilepsy. 
About 30% of all epilepsies account for idiopathic epilepsies. Most forms of epilepsy 
follow a complex mode of inheritance involving multiple genes and environmental 
influences. Hence, because the vast majority of idiopathic epilepsies are complex 
genetic disorders rather than inherited in a simple mendelian manner, causative 
gene identification is challenging. The contribution of genes and environment is 
difficult to measure and boundaries are mostly not very clear leading to an evidence 
for an interaction of genes and environmental factors (Berkovic, 2006). However, 
epidemiological studies show that about 5% of patients have a first-degree relative 
with epilepsy (Bianchi et al., 2003, Vestergaard et al., 2007) and family aggregation 
studies display recurrence risk ratios of around 2.5 in first degree relatives (Annegers 
et al., 1982, Hemminki et al., 2006).  
In addition, twin studies have supported the genetic background of the disease by 
showing significantly higher concordance rates for monozygotic compared to 
dizygotic twins for epileptic seizures and epilepsy (Kjeldsen et al. 2003, Berkovic et 
al., 1998). 
The classification of epilepsy and concepts of their genetics is changing fast. So far, 
many disease causing genes for rare monogenic forms of idiopathic epilepsy are 
identified.  
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1.3 Genetics of epilepsy 
 
The vast majority of genes linked to epilepsy encode proteins which are molecular 
components of the neuronal signalling complex, encoding subunits of voltage-gated 
and ligand-gated ion channels. Collectively, they are classified as channelopathies. 
Ion channels embedded in the cell membrane are gated pores that permit the 
passive flow of ions through the cell membrane against their electrochemical 
gradient (Figure1). They play a major role in nerve and muscle excitation, hormone 
secretion, cell proliferation, sensory transduction, learning and memory, regulation of 
blood pressure, salt and water balance, lymphocyte proliferation, fertilization and cell 
death (Ashcroft, 2000). The hallmark of ion channels is the selective differentiation 
between ion species, allowing some to pass and others not, and the transition 
between open and closed (gating).  
Mutations have been found in voltage-dependent Na+, K+, Ca+, Cl- channels, 
hyperpolarization-activated cyclic nucleotide-gated (HCN) channels and ligand-
gated channels such as nicotinic acetylcholine receptors and Gamma-aminobutyric 
acid (GABA) receptors (Table1).  
However, a number of non ion channel genes have also been identified in which 
mutations were found to cause the disease (Reid et al., 2009). 
Besides high risk genes in monogenic forms, candidate gene approaches in recent 
years have identified a number of low risk susceptibility alleles in complex idiopathic 
epilepsy. These alleles confer only small increments of the individual risk (Odd 1-2) 
and are thought to interact with environmental factors.  
Although, in the last few years genetic discoveries have led to better understanding of 
the molecular and cellular deficits major causative genes for common epilepsies 
remains to be explored.  
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Figure 1: Voltage gated and ligand gated ion channels embedded in the cell membrane. 
Opening and closing is dependent on ligand binding (ligand gated) (a) or transmembrane voltage 
(voltage gated) (b). Reprinted from “From molecule to malady.” by Ashcroft, F.M., 2006 Nature. 440, 
p.440 
 
 
 
1.4 Neurobiology of seizures and epilepsy 
 
The neuronal signalling system is complex and disruption of one component of the 
signal pathway can have disastrous consequences. Thus, diverse fundamental 
components of the central nervous system structure and function serve as possible 
contributors to seizures.  
The nerve cell function and neuronal communication is based on chemical and 
electrical gradients that provide its ionic microenvironment and electrical activity. In a 
normal neuronal cell there is a high intracellular concentration of potassium (K+) and 
a high extracellular concentration of sodium (Na+), as well as additional ions which 
provide a net transmembrane potential of -60mV (Hodgkin and Huxley, 1939; 
Barnett and Larkman, 2007). This unequal distribution of ions is maintained by 
ATPase pumps via exchanging internal Na+ for external K+.  
By opening the voltage gated ion channels an exchange of intra- and extracellular 
ions occur, which leads to a transient reversal (1 millisecond) of the polarity of this 
transmembrane potential termed action potential (Barnett and Larkman, 2007). 
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The rapid reversal of the action potential is initiated by the transient opening of 
voltage-gated potassium channels and inactivation of the voltage-gated Na+ 
channels. The outward current of K+ ions restores the resting potential of the cell. The 
depolarisation of the membrane by the action potential generates local currents in 
the voltage-gated channels along the neuron and therefore allows the conduction of 
the impulse from the dendrite to the axon terminal (Barnett and Larkman, 2007). The 
myelin sheath, formed by the oligodendrocytes, is a multilamellar, wrapped around 
the axons in segments and separated by the nodes of Ranvier. Therefore the fast 
saltatory movement of nerve impulses along the neuron can be provided (Hille, 
2001). At the synapse, voltage-gated calcium channels allow an inward flow of 
calcium ions, and synaptic vesicles containing neurotransmitters are released, thus, 
converting the electrical signal to a chemical signal. The release of neurotransmitters 
activates ligand-gated receptors in the post-synaptic membrane and a new action 
potential in the post-synaptic neuron is generated. Considering this, it appears 
obvious that mutations in components of this signalling way can cause pathological 
neuronal hyperexcitability, the biological background of epilepsy. So far, various 
studies investigated how mutations enhance network excitability. Mutations in the 
subunits of the voltage-dependent sodium and potassium channels alterate ion 
concentrations. Such an increase or decrease of the ion current into or out of the 
neuron modifies the exhibition/inhibition balance and can lead to depolarization and 
resulting action potential discharge (Meisler et al., 2001, Reid et al., 2009). In 
addition, the hyperexcitability of neurons may be due to either reduction of inhibitory 
control mechanisms such as GABAergic interneurons, GABA levels and GABAA 
receptor sensitivity or due to increase of excitatory mechanisms like astrocytes gap 
junctions, glutamate level and NMDA receptor sensitivity (Armijo et al., 2002). 
Blockade of the sodium potassium ATPase in rat hippocampal slice preparations 
induces seizure activity (Vaillend et al., 2002). Furthermore, seizures themselves 
provoke an increase in extracellular potassium and therefore an excessive discharge 
and further depolarization of neurons (Scharfman, 2007).  
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1.5 Classification of seizures and epilepsy syndromes 
 
In 1981, The International League Against Epilepsy (ILAE) developed an international 
classification system for epileptic seizures dividing them into two major groups: (i) 
generalized seizures and (ii) focal seizures. In 1989, ILAE generated a classification 
for epilepsy syndromes. To date, more than 50 syndromes are described subdivided 
into clinical syndromes. (ILAE, 1989; Engel, 2001; Engel, 2006) Clinical features of 
a syndrome include seizure types, their localization, frequency, age of onset, mode of 
inheritance, physical or mental symptoms and signs, and other clinical, 
electroencephalographic and imaging features (EEG/MRI). (ILAE, 1989; Engel, 
2001; Engel, 2006) 
 
1.5.1 Seizure types 
1.5.1.1 Generalized seizures 
Generalized seizures are considered as bilaterally synchronous discharges, 
originating from cortical or subcortical structures or from the whole cortex at once. 
Although generalized seizures are characterized by the involvement of both 
hemispheres seizures can emerge localised. EEG shows generalized spike wave 
activity. However, this location can vary from one seizure to another (Berg et al., 
2010). Generalized seizures are sub-categorized into several seizure types (Engel 
2006; Blume et al., 2001): 
(i) Tonic-clonic seizures formerly known as “grand mal” start with rigid contraction of 
muscles (stiffening) followed by rhythmic shaking (jerking) and loss of consciousness. 
Some individuals can experience the typical tonic-clonic pattern whereas others only 
undergo the tonic or clonic phase.  
(ii) Myoclonic seizures are brief, rapid contractions of the muscles which result in 
sudden jerks.  
(iii) Absence seizures are brief periods of staring that last no longer then a few 
seconds. During the absence awareness and responsiveness are impaired.  
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(iv) Epileptic spasm is characterized by a sudden flexion extension of predominantly 
proximal and truncal muscles (epileptic spasm can also be classified as focal 
seizure).  
(v) Atonic seizures are characterized by a sudden loss or diminution of muscle tone 
lasting 1-2 seconds.  
 
1.5.1.2 Focal seizures 
In contrary, focal (partial) seizures are associated with a focal discharge beginning in 
circumcised regions of mainly cortical structures limited to one hemisphere. Resulting 
symptoms are, accordingly to the involved specific cortical structure, sensory 
sensations or motor signs. Seizures can affect awareness and/or memory. EEG shows 
localized epileptiform activity. Focal seizures can sometimes turn into generalized 
seizures, called secondary generalization.  
 
1.5.2 Genetic epilepsy syndromes  
1.5.2.1 Age-dependent syndromes 
1.5.2.1.1 Newborn to early infancy 
The epilepsy syndromes of infancy comprise benign familial neonatal seizures 
(BFNS), benign familial neonatal-infantile seizures (BFNIS) and benign familial 
infantile seizures (BFIS). These syndromes differ in the age of onset ranging from the 
second day of life to a few months (Berkovic et al., 2004). The syndromes, which 
typically occur in otherwise neurological healthy babies, are characterized by 
unprovoked seizures which end spontaneously after a period of a few months.  
Mutations for these syndromes are found in genes coding for subunits of voltage-
dependent K+ channels (KCNQ2, KCNQ3), voltage-dependent Na+ channels 
(SCN2A) and in the ATP1A2 gene which encodes the alpha subunit of the Na+/K+-
ATPase pump. 
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Febrile seizures (FS) affect 3% of children between 6 months and 6 years of age 
(Sadleir and Scheffer, 2007). Seizures typically appear in combination with fever. 
CNS infection or an acute metabolic disturbance is thought as triggering mechanism 
(Sadleir and Scheffer, 2007). Most FS remit after few years and the child’s 
psychomotor development is unharmed. However, there is an increased risk for later 
development of an adult form of temporal lobe epilepsy (TLE). FS can occur isolated 
or in combination with other epilepsy syndromes. Linkage analyses have identified 
many loci for febrile seizures (Baulac et al., 2004) indicating genetic heterogeneity 
(Berkovic and Scheffer, 2001). To date, not one high penetrant gene has been found 
for this form of epilepsy. 
 
Dravet syndrome (DS) is a severe form of myoclonic epilepsy in infancy. DS starts at 
about the age of 6 months in infants whose development has been normal up to that 
time. Affected children experience febrile or afebrile generalized tonic-clonic seizures 
and unilateral seizures that usually occur on alternating sides (Neubauer et al., 
2008). DS is associated with developmental regression and prognosis of seizure free 
life is pure (Dravet et al., 2005). Most of the patients exhibit mutations in the SCN1A 
gene coding for the alpha1 subunit of voltage-dependent Na+ channels (Reid et al., 
2009). Loss or gain of function mutations result in delayed or impaired inactivation 
of Na+ channels, which lead to an ongoing Na+ current and membrane 
hyperexcitability. However, in some patients mutations in the GABRG2 gene coding 
for the gamma 2 subunit of the GABAA receptor were identified (Reid et al., 2009). 
1.5.2.1.2 Late infancy to adolescence 
Generalized epilepsy with febrile seizure plus (GEFS+) links febrile seizures with 
various other epileptic seizures/syndromes. GEFS+ demonstrates genetic relations 
between (i) benign and severe and (ii) focal and generalised epileptic disorders 
(Panayiotopoulos, 2005). It is characterized by phenotypic heterogeneity in affected 
family members and between different families including classical febrile seizures, 
febrile seizures plus, mild to severe generalised epilepsy and focal epilepsies (Helbig 
et al., 2008). GEFS+ is marked by childhood onset of febrile seizures which start 
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earlier than classical febrile seizures and continue on beyond the age of five years to 
later childhood or adolescence (Panayiotopoulos, 2005). Remission mostly occurs in 
adolescence. Mutations for GEFS+ are detected in SCN1A, SCN1B and GABRG2 
(Reid et al., 2009). 
 
Idiopathic generalized epilepsies (IGE) account for about 30% of all epilepsies 
(Jallon et al., 2001). IGE’s comprise several subsyndromes such as childhood (CAE) 
and juvenile (JAE) absence epilepsy, juvenile myoclonic epilepsy (JME) and the less 
frequent but more severe forms myoclonic astatic epilepsy and Lennox-Gastaut 
syndrome (Reid, 2009).  
Idiopathic generalized epilepsy emerges generally in childhood or adolescence with 
typical absences, myoclonic jerks and generalised tonic clonic seizures. These 
symptoms can occur alone or in combination with each other and are usually life 
long. Genes involved in IGE are: GABRG2, GABRA1 and GABRD genes coding for 
subunits of GABAA receptors, CLCN2 coding for voltage-dependent Cl- channels 
gene, CACNA1H coding for the Cav3.2 subunit of voltage-activated Ca2+channels 
and other genes such as EFHC1, ME2, and NEDD4L (Helbig et al., 2008). 
 
1.5.2.2 Age-independent epilepsy syndromes  
1.5.2.2.1 Focal epilepsy syndromes  
Focal epilepsies account for approximately 50% of all epilepsy patients (Jallon et al., 
2001). Traditionally, focal epilepsies have been largely ascribed to 
acquired/environmental factors such as hippocampal sclerosis, tumours, trauma, 
and vascular malformations. However, in the past decade, the importance of genetic 
factors in partial epilepsies was emphasized. Recurrence risk ratios in first-degree 
relatives of 2-3 (Annegers et al., 1982 Hemminki et al., 2006), the frequent 
observation of familial clustering and a higher concordance rate in monozygotic 
(MZ) versus dizygotic (DZ) twins (Berkovic et al., 1998, Kjeldsen et al., 2003) provide 
clear evidence of a genetic contribution to focal epilepsies.  
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The first familial focal epilepsy for which the genetic background has been elucidated 
was the autosomal-dominant nocturnal frontal lobe epilepsy (ADNLFE)(Scheffer et 
al., 1994).  
ADNFLE is characterized by seizures during nonrapid eye movement (NREM) sleep 
with hypermotor or tonic manifestations and rare tonic clonic seizures. Seizures start 
in the middle to late childhood and become less frequent during adult life. Three 
genomic loci have been found to be linked to ADNFLE, chr20q13.2 (Phillips et al., 
1995), chr15q24 (Phillips et al., 1998) and chr1q (Gambardella et al., 2000) now 
referred to as ADNFLE type 1, 2 and 3 (Hirose et al., 2002). For two of the three loci 
the corresponding gene has been identified.  For ADNFLE type 1 mutations have 
been found in the CHRNA4 gene coding for the alpha4 subunit of the ligand–gated 
nicotinic acetylcholine receptors. Mutations in the CHRNB2 gene coding for the beta 
2 subunit of nicotinic acetylcholine receptors respectively were ascribed to ADNFLE 
type 3.  
 
1.5.2.2.2 Temporal lobe epilepsy (TLE) 
TLE is the most common form of epilepsy in adults. Several temporal lobe epilepsy 
syndromes are acknowledged. They can be either sporadic or familial and 
categorization in familial or non-familial is not always clear without a profound 
genetic study and family history investigation. 
Familial temporal lobe epilepsies are divided into two major subgroups based on 
seizure semiology, genetic background and MRI characteristics: (i) Familial mesial 
temporal lobe epilepsies (FMTLE) and (ii) Familial lateral temporal lobe epilepsies 
(FLTLE) also termed as autosomal-dominant partial epilepsy with auditory features 
(ADPEAF). Most of the familial forms of TLE show an autosomal dominant mode of 
inheritance with incomplete penetrance (Cendes et al., 1998).  
 
FMTLE was first described by Berkovic et al. in 1994. It is characterized by focal 
seizures which have an onset range between the second and the fifth decade of life. 
Seizures are typically preceded by an aura with prominent psychic and autonomic 
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features. Auras are perceptual disturbances manifesting in visual and auditory 
changes or other sensations such as strange smell, gustatory hallucinations, déjà vu 
or fear (Shorvon, 2005). Auras are experienced before a seizure occurs. Patients with 
FMTLE typically show no hippocampal abnormalities (Berkovic et al., 1994). Linkage 
has been described to 4q13.2-q21.3. However, the corresponding gene has not 
been found yet (Hedera et al., 2007).  
 
FLTLE or ADPEAF is a benign syndrome with focal seizures and secondary 
generalization. The focal seizures comprise auditory auras mainly, but complex 
visual, psychic, autonomic, vertiginous and other sensory symptoms can appear as 
well (Michelucci et al., 2003). Patients usually have a normal MRI. The age of onset 
ranges between teenage or early adult life. FLTLE is the first familial epilepsy 
syndrome where mutations were discovered in an non-ion channel gene. In 1995, 
linkage to chromosome 10q was established (Ottman et al., 1995) and in 2002 the 
leucine-rich glioma-inactivated 1 gene (LGI1), was identified as causative in 5 
families with ADPEAF (Kalachikov et al., 2002). LGI1 is thought to be a secreted 
neuronal protein (Fukata et al., 2006) which may play a role for a potassium 
channel via protein-protein interactions (Schulte et al., 2006). However, not all 
families with ADPEAF demonstrate LGI1 mutations indicating genetic heterogeneity.  
 
Familial Partial Epilepsy with variable foci (FPEVF) is an autosomal dominant 
syndrome characterized by different types of focal seizures ranging from frontal, 
temporal, occipital to centroparietal origin (Scheffer et al., 1998). The age of onset 
is variable but mostly occurs in the first three decades. Linkage for this form has been 
described to 2q36 (Scheffer et al., 1998) and 22q12 (Xiong et al., 1999). However, 
the corresponding genes have not been found yet.  
 
1.5.2.2.3  Other rare epilepsy syndromes 
Familial cortical myoclonic tremor with epilepsy (FCMTE) comprises a disease 
spectrum presenting with autosomal dominant inheritance, adult-onset cortical 
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myoclonus and focal or generalized seizures (van Rootselaar et al., 2005). The wide 
phenotypic heterogeneity includes syndromes such as: autosomal dominant cortical 
myoclonus and epilepsy (ADCME), benign adult familial myoclonic epilepsy 
(BAFME), familial adult myoclonic epilepsy (FAME), familial cortical myoclonic tremor 
(FCMT), familial cortical tremor with epilepsy (FCTE), familial essential myoclonus 
and epilepsy (FEME) and familial benign myoclonus epilepsy of adult onset (FMEA). 
In all syndromes myoclonus is usually the first symptom and characterized by 
tremulous finger movements and myoclonus of the extremities increased by action 
and posture (van Rootselaar et al., 2005). Epilepsy is presented by mainly 
generalized tonic-clonic seizures. 
To date, three loci have been mapped but no genes have been identified yet. 
Linkage was shown to 8q23.3-q24.11 in a Japanese family with BAFME referred to 
as FCMTE1/FAME1 (Mikami et al., 1999). The second loci mapped on 2p11.1-
q12.2 (FCTME2/FAME2) and were established in European pedigrees with ADCME 
(Guerrini et al., 2001, Laubage et al., 2002, De Falco et al., 2003, Striano et al., 
2004). Recently a third locus, FCMTE3, mapped to 5q in a large French family 
(Depienne et al., 2010). 
  
For summary of epilepsy syndromes see Table 2. 
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Table 1: Epilepsy genes and their associated syndromes (based on Reid et al., 2009) 
 
Channel Receptor 
 
Gene 
 
Epileptic Syndrome 
Voltage-gated ion channels   
Na+channels SCN1A GEFS+, SMEI 
 SCN2A BFNIS, GEFS+ 
 SCN1B GEFS+ 
   
K+ channels KCNQ2 BFNS 
 KCNQ3 BFNS 
 KCNA1 partial seizures 
 KCNMA1 epilepsy and paroxysmal dyskinesia 
 KCNJ11 epilepsy, neonatal diabetes 
   
Ca+channels CACNA1H IGE 
 CACNA1A epilepsy, episodic ataxia 
   
Cl- channels CLCN2 IGE 
   
HCN1, HCN2 
 
 IGE 
Ligand-gated ion channels   
GABA receptors GABRA1 IGE 
 GABRG2 FS/GEFS+ 
 GABRD IGE/GEFS+ 
   
Neuronal nicotinic acetylcholine 
receptors 
CHRNA4 ADNFLE 
 CHRNB2 ADNFLE 
 CHRNA2 ADNFLE 
Non-ion-channel genes   
 LGI1 ADPEAF 
 ATP1A2 infantile convulsions, migraine epilepsy 
syndromes 
 ME2 IGE 
 EFHC1 IGE 
 SLC1A3 epilepsy, migraine, episodic ataxia 
 MASS1 FS 
 GLUT1 IGE and dyskinesia 
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Table 2: Classification of electroclinical syndromes and other epilepsies (based on ILAE, A. T. Berg et 
al., 2010) 
 
 Electroclinical syndromes and other epilepsies 
 
 Electroclinical syndromes arranged by age at onset 
 Neonatal period 
 Benign familial neonatal epilepsy (BFNE) 
 Early myoclonic encephalopathy (EME) 
 Infancy 
 Epilepsy of infancy with migrating focal seizures 
 West syndrome 
 Myoclonic epilepsy in infancy (MEI) 
 Benign infantile epilepsy 
 Benign familial infantile epilepsy 
 Dravet syndrome 
 Myoclonic encephalopathy in nonprogressive disorders 
 Childhood 
 Febrile seizures plus (FS+) (can start in infancy) 
Panayiotopoulos syndrome 
 Epilepsy with myoclonic atonic (previously astatic) seizures 
 Benign epilepsy with centrotemporal spikes (BECTS) 
 Autosomal-dominant nocturnal frontal lobe epilepsy (ADNFLE) 
 Late onset childhood occipital epilepsy (Gastaut type) 
 Epilepsy with myoclonic absences 
 Lennox-Gastaut syndrome 
 Epileptic encephalopathy with continuous spike-and-wave during sleep (CSWS) 
 Landau-Kleffner syndrome (LKS) 
 Childhood absence epilepsy (CAE) 
 Adolescence – Adult 
 Juvenile absence epilepsy (JAE) 
 Juvenile myoclonic epilepsy (JME) 
 Epilepsy with generalized tonic–clonic seizures alone 
 Progressive myoclonus epilepsies (PME) 
 Autosomal dominant epilepsy with auditory features (ADEAF) 
  Other familial temporal lobe epilepsies 
 Less specific age relationship 
  Familial focal epilepsy with variable foci (childhood to adult) 
  Reflex epilepsies 
 Distinctive constellations 
  Mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE with HS) 
Conditions with epileptic seizures that are traditionally not diagnosed as a form of epilepsy 
per se 
  Benign neonatal seizures (BNS) 
  Febrile seizures (FS) 
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1.6 Molecular approaches for identifying genes 
 
The human haploid genome consists of approximately 3 billion DNA bases divided 
among 20.000-25.000 protein coding genes (International Human Genome 
Sequencing Consortium, 2004). Genetic changes (variation) contribute to human 
diseases but many genetic variations have no pathologic effect. At the molecular 
level, variations mostly occur through (i) structural variants [copy number variants 
(CNV), insertions/deletions, and block substitutions] and (ii) single nucleotide 
polymorphisms (SNP’s) (Frazer et al., 2009). SNP’s are common variants presented 
by the change in a single base with a minor allele frequency of at least 1% in the 
population (Kruglyak and Nickerson, 2001). The majority of SNP’s are silent and do 
not alter the function and expression of the gene. Only a small number confer small 
to moderate effects to the gene. Large biological effects on the phenotype are 
caused by rare mutations which then provoke monogenetic disorders. Mendelian 
genetic diseases can either be dominant (only a single copy of a mutated gene cause 
the disease) or recessive (two mutated alleles of the gene cause the disease) (Mullen 
et al., 2010). However, the majority of diseases are considered to be complex 
implying an interaction of genetic and environmental factors. Two models describe 
the contribution of genetic factors to common diseases. The ‘Common Disease, 
Common Variant’ model (CDCV) postulates that the genetic contribution is mainly 
composed of multiple common variants with small individual risk (relative risk 1.1-
1.5) (Mullen et al., 2009). In contrast, the second model ‘Common Disease-Multiple 
Rare Variant’ (CDMRV) says that multiple rare variants confer a high disease risk 
(relative risk 5-10) in a given population (Mullen et al., 2009).  
 
1.6.1 Linkage Analysis and Positional Cloning of Mendelian disease 
genes 
Linkage analysis is used to map genetic loci that predispose to disease. In linkage 
analysis cosegregation of two or more genes is examined in a pedigree to determine 
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if they segregate independently or if they do not segregate independently because of 
their physical proximity (Wiley et al., 1996). In this way the chromosomal region 
shared by affected members of a large pedigree can be established. Classical 
linkage is performed in large families with many affected members or multiple 
families with few affected individuals in which the same mutant gene is responsible 
for the disease. Naturally occurring crossovers during meiosis limit the candidate 
region shared by affected individuals. Alleles which are close together on the same 
chromosome will tend to be inherited together, rather than separated during meiosis 
(Teare and Barrett, 2005). The pattern of crossovers in the region of the gene among 
the family members leaves a few hundred predicted genes that might be the disease 
causing gene (Botstein & Risch, 2003). Subsequently, systematically sequencing of 
the candidate genes within the linkage region and characterization of their protein 
products and their associated pathways may identify the putative gene. To prove the 
causative role of the mutation, it has to be found in the same gene in unrelated 
families and should show a major impact to the gene function. To infer 
pathogenecity a lower frequency in controls and a clearly altered function of the 
gene product is needed.  
A requirement for successful linkage is a precise and critical assessment of the 
phenotypes of the study cohort to ensure exclusion of phenocopies. Phenocopies are 
defined as family members who have the disease but do not carry the familial 
mutation. They are thought to suffer from the disease either because of another 
genetic reason or because of a non-genetic, probably environmental reason. There 
exists no specific test for any particular disease to distinguish who has the disease 
gene and who is a phenocopy. Accurate clinical diagnosis does not prevent the 
occurrence of phenocopies unless some members show certain unusual 
characteristics of the disease. Correct clinical diagnosis is challenging as clinical 
heterogeneity with the same mutation is a frequent phenomenon. Misdiagnosis, 
heterogeneity, complex inheritance and phenocopies can cause failure of linkage 
analysis (Botstein & Risch, 2003). However, the vast majority of genetic diseases are 
not transmitted in a Mendelian manner and conventional linkage fails.  
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1.6.2 Association Studies 
Association studies are used to detect differences in allele frequencies of genetic 
variations between patients and healthy people. Genotypes of large groups of 
unrelated patients are compared to a control population. An allele is associated with 
the disease if its frequency differs between cases and controls more than would be 
predicted by chance (Lander et al., 1994). Two approaches have been widely used 
in the past few years: (i) Candidate gene-association studies, where a candidate 
gene already exists due to biological or functional considerations. In these cases only 
few SNP’s within the gene region are tested for association. Within the past 10 years 
multiple association studies on epilepsy have been performed and more than 85 
genes have been claimed to be associated with the disease 
(http://geneticassociationdb.nih.gov). However, most of them could not be 
confirmed in replication studies. Especially in epilepsies, where heterogeneity is a 
major variable, findings from association analysis explain little of the disease 
susceptibility (Helbig et al., 2008). The second approach, (ii) Genome-wide 
association studies, screen for association of common variants with a disease 
phenotype across the entire genome (Mullen et al., 2009). In these cases several 
hundred thousand SNP’s across the entire genome are tested for association. The 
advantage of this approach is that no prior assumption of a functional relationship 
between a gene and the disease is needed. However, the huge number of tested 
SNP’s makes a correction for multiple testing necessary. Most nominal significant 
SNP’s (p<0.05) are likely false positive. To separate the true positive SNP’s from 
false positives, either a very strong p value (p<010-8) is needed or a second round 
of genotyping with the best significant SNP’s in an independent study population has 
to be performed. 
Recently, recurrent microdeletion on chromosome 15q13.3, 16p13.11 and 
15q11.2 were identified to constitute a genetic risk factor for common IGE 
syndromes (Helbig et al., 2009; de Kovel et al., 2009; Dibbens et al., 2009). Each 
deletion was found in ~ 1% of affected individuals (Mefford et al., 2010) Notable, 
the 15q13.3 microdeletion was not identified in the control population, therefore it 
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can be seen as the major risk factor for IGE, whereas the other two deletions confer 
a lower genetic risk to IGE (de Kovel et al., 2010). 
However, the size of samples needed for a genome- wide association to attain 
sufficient statistical power is enormous and in epilepsy, the study design is still 
challenging.  
 
1.6.3 Exome Sequencing 
In the past few years sequencing technologies have made great advances. The 
development of “Next generation sequencing” techniques allows the simultaneous 
sequencing of genomic regions in the megabase range within a few days. One 
important application of this technique is the complete analysis of all protein coding 
exons of the human genome (~300.000 )(EXOME sequencing). This powerful 
technique will enhance the identification of familial high risk genes in the near future. 
For a more detailed description see material and methods.  
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2 The Aim of the Study 
 
 
We present a consanguineous Egyptian family with an autosomal recessive 
inheritance pattern suffering from temporal lobe seizures, myoclonus and tremor. We 
established linkage to chromosome 1q31.3-q32.2. The aim of the present study 
was: (i) to identify the causative gene within this family via EXOME next generation 
sequencing (ii) sequencing of the putative gene in 189 temporal lobe epilepsy 
patients from Austria and Italy to test whether this gene contributes to TLE phenotypes 
in general.  
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3 Material and Methods 
 
 
3.1 Study population 
3.1.1 Egyptian family 
We investigated a consanguineous Egyptian family where five of the seven siblings of 
healthy parents show an autosomal recessive inherited epilepsy syndrome (Figure 2). 
The family exhibits a phenotype with temporal lobe epilepsy, myoclonus and tremor 
(Table 3). Patients were examined by a local neurologist at the University of Ain 
Shams in Cairo/Egypt.  
The initial symptoms in all patients were seizures starting between the ages of 11 to 
14 years. The occurring seizures range from complex partial, to secondary 
generalized tonic clonic and to myoclonic seizures of variable frequency. Three 
affected members additionally exhibit auras at the onset with hearing childish or 
illformed voices, olfactory sensations and hallucinations with vivid scenes. All patients 
responded well to Carbamazepine respectively Lamotrigine. For three patients MRI 
screening was performed showing a bilateral mesial hippocampus sclerosis in patient 
IV-7, and was normal in patient IV-3 and IV4. For the other two patients CCT 
screening demonstrated no abnormalities. EEG showed interictally temporal 
epileptiform discharges in three of five affected siblings. Altogether, these features 
suggest a phenotype of temporal lobe epilepsy. Moreover, all five affected patients 
showed a coarse tremor of the head and upper extremities, which did not respond to 
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3.1.2 Temporal lobe epilepsy patients and controls 
 
The control individuals for testing, detected putative pathogenic variants consisted of 
366 healthy Austrian blood donors and 36 healthy Egyptian volunteers. The Austrian 
control subjects (n=366, females=145, males=221) were recruited through the 
Department of Neurology, Medical University of Vienna, as subjects without known 
history of a neurological disorder, such as non blood-related companions. All 
patients and controls were Middle European ancestry. The average age of the 
control group was 40 years. All study participants gave written informed consent and 
the study was approved by the local ethics committee.  
 
For the screening for possible mutations of the CNTN2 gene in a larger sample of 
epilepsy patients we selected 170 Austrian patients and 19 Italian patients with 
temporal lobe epilepsy (n=189, females=81, males=108). However, none of our 
patients exhibit exactly the described phenotype. In addition, the pattern of 
inheritance of our study population varies between sporadic, dominant and likely 
recessive.  
 
 
Figure 2: Pedigree of consanguineous Egyptian family with autosomal recessive mode of inheritance. 
III-1 and  III-2: carrier; IV-1, IV-3, IV-4, IV-6 and IV-7: affected; 
 
 
 
propanolol. Parents of affected siblings gave informed consent and local ethic 
committee approved the study. 
 
   
    
Generalized tonic clonic (GTC), Complex partial seizures (CPS), Upper Extremities (UE), Carbamazepine (CBZ), Lamotrigine (LTG), Cranial computed tomography 
(CCT), Magnetic Resonance Imaging (MRI), Loss of Consciousness (LOC); 
Patient Sex Age Onset Seizure
type(s) 
Seizure description Antiepileptic Drugs EEG Brain 
imaging 
Associated features 
IV-1 M 39 11 GTC No specific aura Controlled on  CBZ Abnormal, 
Not 
specified 
CCT normal Tremor, head and UE 
IV-3     F 37 14 GTC
CPS 
Myoclonus 
LOC with aurobuccal automatism Occasional seizures on CBZ Interictal:  
Left posterior 
temporal 
epileptiform 
discharge 
MRI normal Tremor, head and UE 
IV-4     F 29 11 Aura
GTC 
CPS 
Myoclonus  
Hearing childish voices, LOC, GTC Controlled on CBZ Interictal:  
No 
abnormality 
MRI normal Tremor, head and UE 
IV-6    F 24 12 Aura 
GTC 
CPS 
Myoclonus  
Hallucination with vivid scenes 
(films),  
Hearing illformed voices, 
Bad smell 
LOC with chewing movements 
Difficult to control on  
CBZ and LTG 
Interictal: 
Left tempro- 
parietal 
epileptiform 
discharge   
CCT normal Tremor, head and UE 
IV-7     F 21 11 Aura
GTC 
CPS 
Bad smell, 
Aurobuccal automatism with LOC 
Controlled on CBZ Interictal: 
Right 
temporal 
discharge   
MRI:Bilateral 
mesial 
temporal 
sclerosis 
Tremor 
 
Table 3: Summary of the clinical features of the Egyptian family 
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3.2 Reagents and Instruments 
1x TBE (Sigma-Aldrich, St. Louis, US) 
10x EDTA Buffer (Applied Biosystems, California US) 
40x TaqMan® SNP Genotyping Assay (Applied Biosystems, California US) 
7900 HT Fast Real Time PCR System (Applied Biosystems, California US) 
Affymetrix GeneChip® Human Mapping10K Xba142 2.0 arrays (Affymetrix, Santa 
Clara, US) 
Agarose (Biozym, Oldendorf Germany) 
Sequencing Analysis Software v.5.2 (Applied Biosystems, California US)  
Aqua bidestillata (AccuGene®, Lonza, Verviers, Belgium) 
BigDye® Terminator v3.1 Sequencing Kit (Applied Biosystems, California US) 
BigDye XTerminator® Purification Kit (Applied Biosystems, California US) 
DNA Quant-iT TM dsDNA BR Assay Kit (Invitrogen, Eugene, Oregon US) 
Ethanol (99.9%) (Sigma-Aldrich, St. Louis, US) 
Ethidium bromide (Merck, Darmstadt Germany) 
FastRulerTM DNA Ladder, Low Range (Fermentas International, Canada) 
Genetic Analyzer 3130 (Applied Biosystems, California US) 
IKA® MS 3 Digital vortexer (IKA, Germany) 
LiChrosolv water (Merck, Darmstadt Germany) 
MultiScreen®PCRµ96 plate (Millipore, Billerica, US) 
Pop-7 TM (Applied Biosystems, California US) 
QIAamp® Blood Midi Kit Spin Protocol (QIAGEN, Hilden Germany) 
QubitTM Fluorometer Reader (Invitrogen, Eugene, Oregon US)  
REPLI-g® Mini Kit of Purified Genomic DNA (Qiagen, Hilden Germany) 
Sample Loading Buffer (in house made) 
Staden Package v. 1.5. 
DNA Engine Tetrad® 2 Thermal Cycler (Biorad, California, US) 
Taq DNA Polymerase Kit (Qiagen, Hilden, Germany) 
Type-itTM Fast SNP Probe PCR Kit (Qiagen, Hilden Germany) 
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3.3 Techniques 
3.3.1 Genomic DNA Isolation 
The genomic DNA purification from whole blood was performed according to the 
QIAamp® Blood Midi Kit Spin Protocol. A 2ml aliquot of human whole blood used 
for extracting genomic DNA was added to 200µl protease and briefly mixed. After 
addition of 2.4ml lysis buffer AL and vigorous shaking the homogenous solution was 
incubated in a water bath at 70°C for 10 minutes. 2ml of 99,9% ethanol was added, 
thoroughly mixed, half of the solution transferred to the QIAamp Midi column and 
centrifuged at 1850 x g for 3 minutes. Resulting filtrate was discarded the remainder 
of the solution transferred in the Midi column and again centrifuged. The bound 
DNA was washed with 2 different buffers AW1 with following centrifugation at 4500 
x g for 1 minute and with AW2 centrifuged at 4500 x g for 15 minutes, respectively. 
The purified DNA was eluted in two steps with 300µl buffer AE each time incubated 
for 5 minutes and centrifuged at 4500 x g for 2 minutes. 
 
3.3.2 DNA Quantification 
The double-stranded DNA concentration was measured using DNA Quant-iT TM 
dsDNA BR Assay Kit in conjunction with QubitTM fluorometer reader.  
3µl of each DNA was diluted with buffer and fluorescent reagent up to 200µl and 
measured with the fluorometer.  
Samples were diluted to a working solution of 10ng/µl and stored at -20°C. 
 
3.3.3 Linkage Analysis 
Genome-wide linkage analysis using Affymetrix Human Mapping10K Xba142 2.0 
arrays was performed. Data for linkage analysis were prepared with a modified 
version of Alohomora (Ruschendorf, 2005). Multipoint linkage analysis was achieved 
using Allegro (version1.1d) (Gudbjartsson, 2000). We assumed an autosomal 
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recessive model. The frequency of the deleterious allele was set to 0.001, and the 
penetrance to 99% (q=0.001; f1=0.0; f2=0.0; f3=0.99). 
 
3.3.4 Whole Genome Amplification 
The Whole Genome Amplification based on Multiple Displacement Amplification 
technology (Dean et al., 2002 and 2001) is an isothermal reaction that provides 
uniform amplification of whole genomic DNA of limited samples. A 50µl MDA-based 
WGA reaction generates 30-50µg of product with consistently >10kb in length 
regardless of the starting template (Lasken, 2009). Due to its simplicity and reliability 
MDA is an adequate method for high-throughput applications like DNA sequencing 
and SNP analysis.  
Some of our samples, especially the Italian and Egyptian DNA’s, were limited by the 
amount of DNA template or quality. We performed a whole genome amplification 
using the REPLI-g® Mini Kit of Purified Genomic DNA according to the 
manufacturer’s specification.  
3.3.4.1 Principle and Procedure 
Multiple displacement amplification uses the binding of random hexamer primers 
and phi 29 DNA polymerase, derived from Bacillus subtilis, for strand displacement 
synthesis at a constant temperature (Dean et al., 2002). The phi29 DNA polymerase 
with its extremely high processitivity and strand displacing activity generates high 
yields of DNA by copying the same template multiple times, extending new primers 
and displacing the previously extended product whereby the displaced strand 
functions as a template for replication. (Figure 3) 
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Figure 3: Principle of the whole genome amplification method by multiple displacement amplification. 
Reprinted from www.quiagen.com, 2010  
 
 
Phosphorothioate linkage of the 3´end of the random primers prevents them to be 
degenerated from the 3´-5´exonuclease proofreading activity of the phi 29 DNA 
polymerase (Dean et al., 2001). Additionally the proofreading activity of the phi 29 
DNA polymerase ensures amplification with an error rate of less than 3 x 10-6(Nelson 
et al., 2002).  
 
To obtain lysis and denaturation of the DNA 5µl buffer D1 was added to 5µl purified 
genomic template DNA vortexed and incubated for 3 minutes at room temperature. 
For neutralization 10µl buffer N1 was added and mixed with the master mix 
containing 29µl reaction buffer and 1µl DNA polymerase. To achieve a maximum of 
DNA yield the samples were incubated in a heating block at 30°C for 16 hours and 
terminated by heating up to 65°C for 3 minutes. Although typical DNA yields are 
approximately 10µg per 50µl reaction we performed accurate quantification with 
DNA Quant-iT TM dsDNA BR Assay Kit according to the manufacturer’s instructions.  
All samples were diluted to a working solution of 5ng/µl and stored at -20°C.  
 
Various studies (Berthier-Schaad et al. 2007, Lovmar and Syvänen 2006) already 
used MDA amplified DNA for high throughput DNA arrays and showed excellent 
concordance of genotype between genomic DNA and amplified DNA as well as 
good genome coverage and lowest amplification bias.  
However, imbalanced amplification can lead to genotyping errors. Due to allelic 
dropout or low quality genotype data heterozygous genotypes can be mistaken for 
homozygous.  
  27 
We gross tested the reliability of our wgaDNA in 20 samples by comparing wgaDNA 
and gDNA using Taqman Genotyping assay with a randomly chosen SNP from 
former studies. 
 
3.3.5 TaqMan® Genotyping 
3.3.5.1 Principle and Procedure  
The Allelic Discrimination assay is a multiplexed assay which detects variants of a 
single nucleic acid sequence at the end of the PCR process. The TaqMan® SNP 
Genotyping Assay which consists of two primers and two probes, dual-labelled 
fluorogenic MGB probes, enables genotyping of the two possible variants at the 
single-nucleic polymorphism site in a target sequence. One probe matches to the 
wild type allele and the other probe to the mutated allele allowing biallelic 
genotyping. (Figure 4) The Allelic Discrimination measures the increase in 
fluorescence of the reporter dyes associated with the TaqMan® probes (Applied 
Biosystems, 2010). 
The TaqMan® MGB probes contain a fluorescent reporter dye at the 5’ end of each 
probe (VIC®, FAMTM), and a non-fluorescent quencher (NFQ) at the 3’ end with a 
minor groove binder (MGB). The MGB is a modification which enforces shorter 
probe design resulting in greater differences in Tm values between matched and 
mismatched probes to secure robust allelic discrimination (Applied Biosystems, 
2006).  
In the intact probe during the PCR the reporter dye emission is adequately absorbed 
by the quencher due to their proximity and overlapping absorption spectrum. After 
hybridization of the probe to the template DNA the DNA polymerase extends the 
primer bound to the DNA and cleaves the reporter dye from the probe. The 
separation of the reporter dye from the quencher leads to the characteristic 
fluorescence signal emitted by the reporter and indicates which alleles are present in 
the sample. An increase in either VIC® or FAMTM indicates homozygous genotypes 
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whereas an increase in the fluorescence signal of both reporter dyes signifies a 
heterozygous genotype. 
The increase in the fluorescence signal is measured by the sequence detection 
software (SDS) which displays the results on a scatter plot of allele X versus allele Y 
grouped into four genotype clusters: homozygote for allele 1, homozygote for allele 
2, heterozygote and non template controls (NTCs). 
 
 
 
Figure 4: Different steps of the Taqman allelic discrimination assay. 
Reprinted from “Allelic Discrimination Getting Started Guide” by Applied Biosystems, 2010 
 
 
 
Genotyping was achieved using Type-itTM Fast SNP Probe PCR Kit using standard 
protocols and reagents. 
8µl Genotyping reaction mix, consisting 5µl Type-it Fast SNP PCR Master Mix, 0.25µl 
40X TaqMan® SNP Genotyping Assay, 2.75µl Aqua bidestillata was added to 20ng 
DNA and conducted using optical 96-well reaction plates on a 7900 HT Fast Real 
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Time PCR System. The TaqMan® SNP Genotyping Assay was for a SNP located on 
chromosome 10q24.32 in the gene PITX3 which was randomly chosen and had no 
further significance for us.  
Standard cycling conditions were the initial PCR activation step for 5 minutes at 95°C 
for activation of the HotStarTaqPlusDNA Polymerase followed by 40 cycles of 
denaturation at 95°C for 15 seconds and annealing at 60°C for 30 seconds. Before 
and after the PCR step Allelic Discrimination reads were performed. 
 
In all 20 cases the amplified DNA gave the correct genotype. The results were 
indistinguishable from the unamplified genomic DNA. (Figure 5) 
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Figure 5: Scatter plot of Taqman allelic discrimination assay for validation of the whole genome 
amplification. 
Demonstrated are results of testing the whole genome amplified DNA versus the genomic DNA, to 
ensure correct amplification. The vertical axis is the mutated allele, labelled with VIC® and the 
horizontal axis is the wild-type allele, labelled with FAMTM.. Non-template controls are plotted as 
black squares.  Dark blue dots on the upper left side are indicating homozygous mutated samples, 
green dots in the middle indicating heterozygous samples, red dots on the lower right side indicating 
homozygous mutated samples. Detail shows two bright blue dots referring once to the amplified DNA 
and once to the genomic DNA demonstrating no difference between amplified and genomic (non-
amplified) DNA. 
 
 
Taqman allelic discrimination assays were developed to screen the normal control 
panel for all three variants derived from the Exome sequencing and for all seven 
novel heterozygous variants resulting from subsequent capillary sequencing using 
20ng of DNA as previously described above. All three variants resulting from the 
Exome sequencing were additionally screened in 189 TLE patients and in the 
Egyptian family.  
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3.3.6 Next-Generation Sequencing 
3.3.6.1 Principle and Procedure 
Next-Generation sequencing enables massively parallel sequencing of many 
thousands or millions of sequencing reactions rather than 96 as conventional 
sequencing machines achieve at a time. Traditional sequencing produces read 
length around 400-800bp whereas next-generation sequencing, depending on the 
platform, generates far shorter reads which can then be compared to a reference. 
Additionally, priory template amplification as in conventional sequencing is 
unnecessary. To date, various next-generation DNA sequencing platforms are 
available (for review, Shendure & Ji, 2008; Mardis, 2007; Tucker et al., 2009). 
Although, the different platforms vary in sequencing biochemistry and array 
generation, their work flows are conceptually similar (Shendure & Ji, 2008). 
 
3.3.6.1.1 Illumina sequencing technology 
Illumina sequencing platform is based on the concept of sequencing by synthesis and 
uses reversible terminator-based sequencing chemistry (Bentley et al., 2008). 
Libraries can be generated by any method creating adaptor ligated DNA fragments. 
Fragments are added to the surface of a glass flow cell which has covalently 
attached oligos complementary to the specific adaptors. Solid-phase bridge 
amplification (Adessi et al., 2000; Dedurco et al., 2006) occurs by adding unlabeled 
nucleotides and polymerase and double stranded bridges are built. Complete 
amplification results in several million dense clusters, each containing ~1.000 
copies of the same template (Illumina Sequencing Technology, 2010). Modified 
sequencing chemistry, consisting of four differentially labelled fluorescent nucleotides 
and polymerase, only allows single-base incorporation in each cycle. Subsequent 
laser excitation provokes the fluorescence signal. After sequencing, the reads are 
aligned to a reference genome and subjected to a quality filtering.  
The paired-end module yields two independent reads derived from each end of the 
template instead a single-end read (Illumina Sequencing Technology, 2010). 
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3.3.6.2 Whole Exome Sequencing 
Whole Exome Sequencing is a second-generation method for targeted sequencing of 
all protein-coding regions. Although costs of Whole Genome Sequencing are 
reducing, Whole Exome Sequencing is a good alternative. By exome sequencing, 
candidate genes for mendelian disorders can be identified within a small number of 
unrelated, affected individuals. (Ng. et al., 2009). 
 
3.3.6.2.1 Exome Sequencing 
Whole Exome Sequencing was performed for two members of the Egyptian family 
(IV-3, IV-6) by our cooperation partner (Department of Human Genetics, Helmholtz 
Center, Munich). Libraries for the two exomes were prepared following standard 
protocols using the SureSelect whole Exome Assay. Sequencing of post-enrichment 
libraries was carried out on an Illumina Genome Analyzer IIx as 54bp paired-end 
runs. For each sample two lanes of a flowcell were sequenced. Image analysis and 
base calling was carried out using the Genome Analyzer Pipeline version 1.5 with 
default parameters. 
 
3.3.6.2.2 Read Mapping 
Alignment of the reads to the hg18 reference sequence was performed with the BWA 
software (v.0.5.8) using mainly default parameters. Reads were trimmed of low 
quality bases at the end (-q) using a cutoff quality of 15. A small number (3-4%) of 
duplicated reads, which were indicated by identical outer coordinates of mapped 
mate pairs, were removed. The percentage of reads overlapping targeted regions 
and coverage statistics of targeted regions were calculated using Perl scripts. 
Mapped reads that directly overlapped the targeted regions were used for variant 
identification. 
About 6.5-7.0 gigabases of mapable sequence data were generated per individual 
with 34-39% of reads mapping to the target regions. On average, >98% of the 
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targeted bases were covered at least once, and > 75% of bases were covered 20 
fold or more. 
 
3.3.6.2.3 Variant Calling 
Initially, 29185 and 29755 variants for the two samples including SNP’s and indels 
using SAMtools (v. 0.1.7) were called respectively. For the variant filter part of 
SAMtools the default parameters with the exception of setting a maximum read depth 
of 9999 (parameter-D) was used.  
Additional filters were applied to exclude low confidence variants: Median base 
quality of the variant base of at least 15, a minimum of 15% of reads showing the 
variant base and that the variant base is indicated by at least 5% of reads coming 
from different strands. For indels it was required that at least 10% of reads covering 
this position to indicate the indel. 
 
3.3.6.2.4 Variant Annotation 
Variant annotation was performed using custom Perl scripts. For prioritization known 
SNP’s from dbSNPv1.30, from eight sequenced exomes of Hap Map samples (Ng et 
al., 2009) and from the in-house database were excluded. 
Finally, the analysis was confined to the linkage region chr1:195653469-
208175909 and all variants that were shared between the two samples were 
selected. 
 
 
3.3.7 DNA Capillary Sequencing 
For identifying further mutations in the CNTN2 gene we performed directed capillary 
sequencing. We screened the candidate gene in three family members of the 
Egyptian family and in 189 TLE patients. The sequencing reaction was carried out 
using BigDye® Terminator Cycle Sequencing kit v.3. Primer design was achieved 
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using Primer3 software. For amplification of exon sequences and exon-intron 
boundaries the following intronic primers were selected: 
 
Table 4: Primer sequences for capillary sequencing of 22 coding exons 
Exon Sequence 
exon 2 forward CTCCCCAGGTCCTTTCTCAG  
reverse TCGTCACCCAAATCATAGCA 
exon 3-4 forward ACAGCACAGCCCAAGAGG 
reverse TCTCAGTAATTTCTCCTAGCCCC 
exon 5 forward GTGAAGGATGAGTCGGGGAG  
reverse CCTCTGCCAAGCATCTGG 
exon 6 forward GAGTGGCCCTGTTAGCCC  
reverse AAACCCTTTTCCTAATGCCC 
exon 7 forward AGTTGGCTCTGAAAGGTGCT  
reverse CCTGTGAGGGACACCAAGAT 
exon 8 forward ACTGGAGGGGTAGGCCC  
reverse CTTGGGGACAAGGGTGAAG 
exon 9 forward GCTGCCCTGATTTTCTGTTC  
reverse GGAACCAAGTGAGCAGAGGAC 
exon 10 forward CCTCCCTGTGGCTCCTG  
reverse CCACAGGGTATGTGCATGTG 
exon 11-12 forward AAAGGGCACGCCAAGTAAC  
reverse GGGGAGGACAGTACCCTGAG 
exon 13 forward CCTGGGCCCATTTCCT  
reverse ATGGCTAAGGACATCTTGGG 
exon 14 forward TGGAGTAGGGGACTCCCAAG  
reverse CAGCTTTGAGGGAAGGGAG 
exon 15 forward TGGCTCAAATTGGAAGCTG  
reverse TCCACCTCCTACACCCAGTC 
exon 16 forward GGTGATTCAGGCCAGTGC  
reverse ATAAGTGGTGCCAGGGTCTC 
exon 17 forward CTCTACAGGCACAGGCTCAG  
reverse CTGCTCAAGCGGGAGAGG 
exon 18 forward CTTGGCAAAGGTTGGGTG  
reverse ATCCCTGTGGACAAGTGGC 
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exon 19 forward GCTCTGCAGGACACAGGG  
reverse CTGTGAGTTGTTCCCACCTG 
exon 20 forward GAGAGGAACAGAATGTGGGG  
reverse AGAGGCACCCACCCTCC 
exon 21 forward AAACATCCAGAGAAGGGCTG  
reverse TGCTGCTGCTTATGTTCACTG 
exon 22 forward GGGATGACTCAACGATCAGC  
reverse GTGGGAATGATCCTCTCAGG 
exon 23 forward AAGGGTGGGGCTAGGGTAG  
reverse ACCTTGGCAGCAGGAAG 
 
 
3.3.7.1 DNA Template Preparation 
Cycle sequencing generates the most reproducible results for sequencing amplified 
templates. We performed PCR using Taq DNA polymerase kit. The PCR amplification 
was carried out with primers flanking the region of interest in the target DNA. 
 
3.3.7.2 PCR reaction optimization 
To ensure successful amplification of the sequence with primer sets of interest, 
optimization was performed for all 20 primers. Standard PCR reaction with different 
annealing time as well as PCR reaction with Q-Solution was set up, respectively.  
Primer were synthesized with standard HPLC purification and ordered in lyophilized 
form at Sigma Aldrich. According to the manufacturer’s protocol, primers were 
dissolved with H2O to a final concentration of 100pmol/µl. The PCR reaction was 
carried out with a 1:10 dilution of the primer stock. 
The standard PCR reaction mix for a 10µl approach with 16ng DNA consisted of 1 
µl 10xPCR buffer, 0.2µl dNTP’s (10mM each), 0.2µl primer forward (10pmol/µl), 
0.2 µl primer reverse (10pmol/µl), 6.33µl dd H2O and 0.07µl Taq polymerase 
(5U/µl). For the reaction mix with Q-Solution 1.2µl 5xQ-Solution was added and dd 
H2O was accordingly reduced. Sequence reaction was carried out using Biorad 
Tetrad® 2 thermal cycler. 
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A simplified hot start was performed to avoid mispriming and primer-oligomerization. 
The PCR program was started and once the thermal cycler reached 95°C the plate 
was placed in the cycler. Thermal cycler conditions were set to the initial 
denaturation step at 95°C for 5 min, followed by 35 cycles at 94°C for 30 seconds 
(denaturation), 50°C-70°C for 30 seconds (annealing) and 72°C for 30 seconds 
(extension) completed with the final extension at 72°C for 10 minutes. Optimal 
primer annealing temperatures were determined empirically by a temperature 
gradient between 50°C and 70°C.  
 
All PCR products were subsequently analyzed on a 2% ethidium bromide-stained 
agarose gel. The agarose gel, composed of 200µl 1x TBE, 4g agarose and 5µl 
ethidium bromide (10mg/ml), was loaded with 8µl PCR product mixed with 2 µl 
loading buffer. Additionally 3µl of low range FastRuler™ DNA Ladder for validating 
the amplified product size was applied. Gel electrophoresis was carried out at 100 
volt for 45 minutes.  
 
3.3.7.3 PCR Reaction 
Once the corresponding conditions for each exon were achieved the template 
generation was performed.  
The PCR reaction mix was adjusted for 30µl with 25ng of template DNA. 
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Table 5: PCR condition for each exon with corresponding mastermix and primer annealing 
temperature 
 
 
Mastermix 
 
Exon 
 
 
Primer annealing 
temperature 
exon 02 56°C 
exon 03-04 57°C 
exon 05  57°C 
exon 06  56°C 
exon 07  62°C 
exon 08  62°C 
exon 09  58°C 
exon 11-12  59°C 
exon 13   61°C 
exon 14  59°C 
exon 15   59°C 
exon 16  62°C 
exon 18  58°C 
exon 21  58°C 
exon 22  59°C 
exon 23  60°C 
 
Standard PCR reaction mix: 
3µl 10xPCR buffer 
0.6µl dNTP’s (10mM each) 
0.6µl primer forward (10pmol/µl)  
0.6 µl primer reverse (10pmol/µl) 
20µl dd H2O and 
0.21µl Taq polymerase (5U/µl) 
  
exon 10  60°C 
exon 17  58°C 
exon 19  58°C 
exon 20  61°C 
PCR reaction mix with Q-Solution: 
3µl 10xPCR buffer 
3.6µl Q-Solution 
0.6µl dNTP’s (10mM each) 
0.6µl primer forward (10pmol/µl)  
0.6 µl primer reverse (10pmol/µl) 
16.4µl dd H2O and 
0.21µl Taq polymerase (5U/µl) 
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Sequence reaction was carried out using Tetrad® 2 Thermal Cycler as described 
above. DNA quality and approximate quantity was determined by loading 8 µl of the 
PCR products on an agarose gel as described above. Purified DNA run as a single 
band on the gel.  
 
3.3.7.4 Template Purification 
Before sequencing PCR product purification is necessary for providing optimal 
results. Contaminations in the sequencing reaction have a negative effect on 
polymerase binding, amplification or extension (Applied Biosystems, 2009). To 
remove contaminating salts, unincorporated dNTP’s and non-specific PCR products 
(primer-dimer artefacts and secondary PCR product) purification with the 
MultiScreen® PCRµ96 plate was performed according to the manufacturer’s 
instructions. 
The volume of the PCR reactions was adjusted to 100µl with dd H2O and the 
reactions were transferred to the MultiScreen® PCRµ96 plate. The plate was placed 
on a vacuum manifold and applied to vacuum at 20 inches Hg until the wells were 
empty. DNA was washed with 50µl H2O, mixed several times within each well and 
vacuum filtration repeated. Purified samples were dissolved in 25µl H2O by shaking 
on a plate shaker at 1000rpm for 10 minutes.  
Samples were retrieved from the purification plate and transferred into a 96-well 
plate. 
 
3.3.7.5 Cycle Sequencing 
3.3.7.5.1 Principle and Procedure 
DNA sequencing was first described by Sanger et al. in 1977. Based on the principle 
of DNA replication sanger dideoxy sequencing, a method where dideoxynucleotides 
triphosphates (ddNTP’s) function as DNA chain terminators, has undergone a 
process of subsequent improvements. Increased efficiency and accuracy has led to 
high-throughput semi-automated sequencing technology (Hunkapiller et al., 1991). 
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Automated cycle sequencing is a process of rounds of denaturation, annealing and 
extension, which results in linear amplification of extension products. (Figure 6) The 
reaction mix contains DNA template, a sequencing primer, DNA polymerase, 
nucleotides (dNTP’s), reaction buffer and dideoxynucleotides (ddNTP’s) which lack 
the 3’-hydroxyl group essential for the phosphodiester bond formation. Each round 
of primer extension is terminated by the incorporation of one of the four fluorescent 
dye-labelled dideoxynucleotide triphosphates.  
The sequence is determined by high-resolution capillary electrophoresis using a 
denaturising flowable polymer. The purified buffered sequence reaction is exposed to 
high voltage and the negatively charged fragments move into the capillaries toward 
the positive electrode. The fragments are separated by size based on their total 
charge. Passing a laser beam each dye emits a unique wavelength and the 
fluorescent dye on the extension product identifies the 3’ terminal dideoxynucleotide 
as A, G, C, or T (Applied Biosystems, 2009).  
 
 
 
 
 
 
 
Figure 6: Principle of dye terminator cycle sequencing. 
Reprinted from “DNA Sequencing by Capillary Electrophoresis Chemistry Guide.” by Applied 
Biosystems, 2009 
 
 
 
We performed cycle sequencing in a 96-well reaction plate using BigDye® 
Terminator v3.1 Cycle Sequencing Kit. The volume of the 2.5xready reaction premix 
was reduced to 2µl and accordingly adjusted for a 20µl approach. Therefore, 3µl 5x 
BigDyeSequencing buffer, 0.5µl primer either forward or reverse (3.2pmol), 5µl 
template DNA and 9.5µl ddH2O were added. Template quantity was adapted 
according to the manufacturer’s protocol.  
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Sequence reaction was carried out using Tetrad® 2 thermal cycler. Cycling 
conditions were rapid thermal ramp to 96°C and initial denaturation at 96°C for 1 
minute followed by 30 cycles at 96°C for 10 seconds, 50°C for 5 seconds and 60°C 
for 4 minutes. Reaction was completed with a rapid thermal ramp to 4°C.  
 
3.3.7.6 Extension Product Purification 
To prevent coinjection of unlabeled and dye-labelled reaction components with the 
extension products, purification of the product needs to be performed. Purification 
was carried out with BigDye Xterminator® Purification Kit according to standard 
protocol. 10µl extension product from the sequencing reaction was transferred in an 
optical 96-well reaction plate. 10µl XTerminator Solution was mixed with 45µl SAM 
Solution and directly added to the sequencing reaction products. The plate was 
vortexed for 30 minutes at 2000rpm to capture and immobilize unwanted 
components. The centrifugation moved the insoluble fraction and captured reaction 
components to the bottom of the reaction well, whereas the purified extension 
products remained in the supernatant.  
The plate was either stored at 4°C or immediately placed in the Genetic Analyzer 
3130.  
 
3.3.7.7 Capillary Electrophoresis 
Capillary electrophoresis was performed on the Genetic Analyzer 3130 using Pop-
7TM run module BDx_UltraSeq36_Pop7. For shorter exons run time was reduced. 
EDTA buffer and LiChrosolv H2O were used according to standard protocol.  
 
3.3.8 Data Analysis 
Primary sequencing analysis was performed with Applied Biosystems Sequencing 
Analysis Software v.5.2 to process raw data into DNA sequence using KBTM 
basecaller, which assigns a base to each peak and provides per-base quality value 
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(QV) predictions. Accurate analysis and alignment was achieved using Staden 
Package v. 1.5. Each chromatogram was visually inspected for the presence of a 
putative variant.  
 
3.3.9 In Silico Analysis 
Assessments of the cross-species conservation of the CNTN2 amino acid sequence 
were performed.  
Predictions of the effects of amino acid substitution were performed with PolyPhen2.  
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4 Results 
 
 
4.1 Clinical data 
 
We identified a consanguineous Egyptian family where five of the seven siblings are 
affected suffering from autosomal recessive inherited epilepsy syndrome associated 
with myoclonus and tremor suggesting a phenotype of temporal lobe epilepsy. For 
details see Material and Methods section. 
 
4.2 Genetic Data 
4.2.1 Linkage Analysis of the Egyptian family 
We performed Genome-wide linkage analysis in the five affected family members. 
Under an autosomal recessive model, significant linkage with a LOD score of 3.6 on 
chromosome 1q31.3-q32.2 between rs927510 and rs724054 was obtained. This 
region extends 12.5Mb and contains 136 genes (Figure 9a, b).  
 
4.2.2 Whole Exome Sequencing  
Whole Exome Sequencing was performed for two members (IV-3, IV-6) of the 
Egyptian family by our cooperation partner (Department of Human Genetics, 
Helmholtz Center, Munich, HMGU). 
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Initially, the screening of the two samples showed 29185 and 29755 variants, 
respectively including SNP’s and indels. A number of prioritization steps were applied 
to reduce the amount of variants. To identify a potentially pathogenic mutation we 
focused on nonsynonymous variants, splice site acceptor and donor site mutations 
and coding indels. Variants whose features did not meet quality-control standards 
were eliminated. We applicated the following filters: (i) Removing variants which are 
present in either the Single Nucleotide Polymorphism Database version 130 or in the 
eight sequenced exomes of the HapMap samples or in different exomes sequenced 
at the HMGU and (ii) exclusion of all variants outlying the linkage region. After this 
filtering, three homozygous variants which were predicted to result in amino acid 
changes were left (Table 6).  
(i) DEAD (Asp-Glu-Ala-Asp) box polypeptide 59, (DDX59) harboured a single 
nucleotide variant c.844G>C that introduces a missense mutation at position 282 
resulting in an amino acid transition from glutamine acid to glutamine (E282Q). This 
gene is rarely expressed in the brain and may play a role in ATP binding and helicase 
activity.  
(ii) Troponin I type 1, (TNNI1) exhibits a single nucleotide variant c.506C>A that 
introduces an amino acid change from serine to tyrosine at position 169 (S169Y). 
TNNI1 is expressed in cardiac and skeletal muscle only. The encoded protein inhibits 
calcium-mediated conformational changes in actin-myosin complexes and thus 
prevents muscle contraction. 
(iii) The third variation a homozygous single nucleotide deletion c.503_503delG in 
Contactin 2 gene, (CNTN2) also termed TAG-1, in exon 6 at the amino acid position 
168 results in a frameshift onwards of this position. CNTN2 is a 
glycosylphosphatidylinositol (GPI)-anchored neuronal membrane protein that 
functions as a cell adhesion molecule and may play a role in the formation of axon 
connections in the developing nervous system. The deletion is located in the Ig-like 
C2-type 2 domain of the protein and therefore yields to a loss of function, making 
this gene the most likely candidate gene.  
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Table 6: Exome Sequencing: Variants shared by the two individuals after prioritization.  
Gene Exon Nucleotide Amino acid 
DDX59 3 c.844G>C E282Q 
TNNI1 7 c.506C>A S169Y 
CNTN2 6 c.503_503delG Frameshift 
 
 
 
4.2.3 Genotyping of DDX59, TNNI1 and CNTN2 variants 
We genotyped all three putative pathogenic variants (i) in 8 members of the Egyptian 
family [5 affected children (IV-1, IV-3, IV-4, IV-6 IV-7), one healthy child (IV-2) and 
two healthy parents (III-1, III-2)], (ii) in 170 Austrian and 19 Italian TLE patients and 
(iii) in 366 Austrian and 36 Egyptian healthy controls. All three variations were 
confirmed to be in a homozygous state in all affected subjects of the family and in a 
heterozygous state in both healthy parents (Figure 7). None of these variants were 
present in the screened Austrian and Italian TLE patients and Austrian and Egyptian 
controls.  
 
4.2.4 Capillary Sequencing of the CNTN2 gene 
Based on previous published animal studies (Fukamauchi et al., 2001; Poliak, et al., 
2003; Traka et el., 2003; Brew et al., 2007), expression data (focusing on 
expression in the brain) and the impact of the mutation (loss of function mutation), 
we considered the CNTN2 gene as the most likely candidate. To test whether 
CNTN2 is a more general contributor to TLE we screened all 22 coding exons of this 
gene in 189 Austrian and Italian patients and in three members (III-1, IV-1 and IV-7) 
of the Egyptian family using capillary sequencing.  
We identified 21 coding sequence variants in our study population (Table 8). Twelve 
of these variants lead to nonsynonymous amino acid substitutions, of which seven 
were not previously reported in dbSNP 130. Nine variants were synonymous, of 
which three were already deposited in the SNP database 130.  
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Each of the seven novel missense variants was genotyped in 366 neurologically 
normal control samples using the Taqman allelic discrimination assay. To assess the 
frequency of rare variants (in the CNTN2 gene) in the general population, our 
cooperation partner in Munich, evaluated Whole Exome Sequencing data from 72 
non-epileptic individuals.  
In particular, capillary sequencing revealed seven nonsynonymous coding variants 
(Table 7, Figure 9e). We detected a heterozygous missense variation, c.214C>T, in 
exon 3 leading to an amino acid change from arginine to tryptophan on position 72 
(R72W). R72W lies in an evolutionary conserved area and a clearly protein 
damaging effect is predicted by PolyPhen. It was not present in any of our control 
individuals. 
We found two heterozygous missense variants in exon 8: c.862G>A resulting in a 
protein change from glutamine acid to lysine at position 288 (E288K). For this 
variation, found in an Italian patient, the evolutionary conservation is slightly weaker 
but is still predicted to be possibly damaging and not present in the control 
population. The second variation in exon 8, c.947C>T induces the amino acid 
substitution threonine to isoleucine at codon 316 (T316I). T316I lies in an 
evolutionary conserved region, is predicted to be a benign variation and present in 
five Austrian control individuals.  
In two patients we detected the variation c.1405 C>A in exon 12. The amino acid 
alteration is a proline to threonine change on position 469 (P469T). One of the 
patients shows a positive family history. This variant is predicted to be benign and not 
found in Austrian controls but in one individual of the 72 exome controls.  
The fifth variant, c.1460C>T, in exon 12 induces a substitution from the amino acid 
threonine to isoleucine at codon 487 (T487I). T487I also located in an evolutionary 
conserved area, is predicted to have a protein damaging effect and was found twice 
in our control population.  
In exon 16 we found the variation c.2057T>C. This variation is marked by an amino 
acid transition from isoleucine to threonine at the position 686 (I686T). I686T is 
predicted to be benign and was not present in the control cohort. 
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In exon 18 we discovered a double nucleotide variant (c.2273-2274GG>AT) 
provoking a change from tryptophan to tyrosine (W758Y) in an individual with a 
positive family history. The deceased grandfather was reported to suffer also from a 
nonspecified epilepsy syndrome. W758Y shows a clear protein damaging effect, 
considerable evolutionary conservation and absence in both control cohorts.  
 
Evaluation of Whole Exome Sequencing data from 72 non epilepsy patients from the 
Munich database revealed four rare nonsynonymous coding variants not deposited 
in the dbSNP130: (Table 7) 
One variant, P469T, was already found in two of our patients. The second variant 
detected, c.505C>T in exon 6, provokes an amino acid change from leucine to 
phenylalanine (L169F). For this variation no protein damaging effect is predicted by 
PolyPhen. The third identified variation c.1294_1295insG is a single base pair 
insertion in exon 11. The last variation, c.2701C>T, was found in exon 20 inducing 
an amino acid substitution from proline to serine (P901S). PolyPhen predicts a 
protein damaging effect for P901S.  
 
In total, capillary sequencing of patients and evaluation of exome data from control 
individuals revealed 35 distinct variations in the CNTN2 gene (Table 8).  
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Figure 7: Scatter plot of Taqman allelic discrimination assay of the genotyped c.503-503delG 
mutation in the Egyptian family. 
Plotting wt allele (G) versus mutated allele (delG). The vertical axis is the G allele, labelled with VIC® 
and the horizontal axis is the mutated allele with the deletion, labelled with FAMTM.. Non-template 
controls are plotted as black squares. Heterozygous parents (green dots), homozygous affected 
siblings (red dots) and homozygote wild type GG in the healthy sibling (blue dot) are genotyped 
accordingly. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
homozygous -/- 
NTC 
homozygous G/G 
heterozygous G/- 
   
cDNA numbering is based on the reference gene uc001hbr.1 for CNTN2 where +1 corresponds to the A of ATG start translation codon. Familial cases are given in 
square brackets. Possibly d.: possibly damaging; probably d.: probably damaging. The variant allele was denoted as '1', the reference allele as '2'. 
Table 7: Rare CNTN2 variants in cases and controls 
Austrian controls 
 n= 366 
Cases 
counts 
Exome Controls 
n=72 
counts 
Exon     
   
Genomic position Nucleotide change Protein change PolyPhen
Prediction 
1/1 1/2 2/2
1         3 205027192 c.214C>T R72W probably d. 366
          1 6 205028229 c. 505C>T L169F benign
1           8 205030437 c.862G>A E288K possible d.
 
366
1        8 205030522 c.947C>T T316I benign  5 361
          1 11 205033504 c.1294_1295insG
2/ [1]          1 12 205033764 c.1405C>A P469T benign 366
1       12 205033819 c.1460C>T T487I probably d.  2 364
1          16 205036310 c.2057T>C I686T benign 366
[1]        18 205039031 c.2273_2274GG>AT W758Y probably d. 366
          1 20 205041231 2701C->T P901S possible d.
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Figure 8: Schematic representation of evolutionary conserved areas in different vertebrates of the 
seven rare nonsynonymous coding variants detected by capillary sequencing.  
 
 
Homo sapiens (human), Pan troglodytes (chimpanzee), Mus musculus (mouse), Rattus norvegicus (rat), 
Gallus gallus (chicken) and Danio rerio (zebrafish). Corresponding amino acid is indicated in bold.  
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Figure 9: Linkage mapping and subsequent sequencing identifies a CNTN2 mutation in an Egyptian family and 
heterozygous missense variations in patients with TLE. 
(a, b) Genome-wide linkage analysis yields significant positive LOD score on Chr1q31.3-q32.2 defining a 
possible new locus between rs927510 chr1:195653470 and rs724054 chr1:208175909. (c) Sequence traces 
of a control sample (WT) and of two members of the Egyptian family. Individual IV-6 carries a homozygous 
deletion (c.503_503delG) in exon 6 of the CNTN2 gene and the parents demonstrate the c.503_503delG 
mutation in a heterozygous state, respectively. (d) Exon structure of human CNTN2 transcript and the 
corresponding protein domain structure consisting of 6 Ig-like and 4 Fibronectin type III domains. The CNTN2 
gene extends over 1040aa and contains 22 coding exons (vertical hatches). Arrows indicate positions of detected 
variations relative to exons and protein domains. (e) Sequence traces of the seven rare heterozygous CNTN2 
variations detected in 189 TLE patients. Variation and predicted translational changes are indicated. None of the 
variations were present in controls except T316I, T487I and P469T.  
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Table 8: All CNTN2 variations found in 189 TLE patients and 3 Egyptian family members and 72 
exome controls 
Genomic position 
on 
chromosome 1 
Exon/ 
Intron 
Nucleotide Aminoacid Comment Cases 
n= 192 
Controls 
Exome 
n= 72 
Exon nonsynonymous 
205027192 3 c.214C>T R72W    1/182  
205027737 5 c.433G>A A145T rs2275697 50/185 20/72 
205028229 6 c. 505C>T L169F    1/72 
205030437 8 c.862G>A E288K    1/192  
205030522 8 c.947C>T T316I    1/192  
205031116 9 c.1097C>T P366L rs2229866 99/190 39/72 
205033504 11 c.1294_1295insG     1/72 
205033518 11 c.1309C>G V437L rs79431021  6/185  5/72 
205033764 12 c.1405C>A P469T   2/185  1/72 
205033819 12 c.1460C>T T487I   1/185  
205035727 15 c.1974A>G N659D rs41264871  2/187  2/72 
205036310 16 c.2057T>C I686T   1/188  
205039031 18 c.2273-2274GG>AT W758Y   1/188  
205041231 20 2701C->T P901S    1/72 
205042840 23 c.3070G>A V1024I rs17416074 12/186 10/72 
Exon synonymous 
205027083 3 c.105C>T F35F    1/182  
205027390 4 c.297C>T N99N rs9787172 10/182  8/72 
205027790 5 c.486A>C P162P rs114050151 11/185  3/72 
205030397 8 c.822C>T R274R    1/192  
205030406 8 c.831C>T D277D    1/192  
205034390 13 c.1695G>A V565V    1/186  
205039627 19 c.2447C>T P816P    1/188  
205041158 20 c.2628C>T S876S rs2229868 77/190 29/72 
205041179 20 c.2649G>A K883K    1/190  
Intron non-coding 
205027496 4 IVS4+12G>A  rs16855012   1/72 
205028438 6 IVS6+18G>T  rs872379 10/178  
205028827 7 IVS7+17insG  rs5780262 40/189  
205028884 7 IVS7+74-75delAG  rs35182846 77/189  
205030587 8 IVS8+39C>T  rs41310859 11/192  
205031744 10 IVS10+47G>A  rs2242001 56/191  
205031769 10 IVS10+72G>A  rs2242000 56/191  
205033650 11 IVS11+50A>G  rs11804498 1/185  
205034434 13 IVS13+44G>T  rs3901740 38/186  
205034853 13 /GACCACCGGCCCTGAC 
CAGTGCAGCAGGCCA 
 rs3217591 137/186  
205038731 17 IVS17+42C>T  rs2305275 64/186  
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5 Discussion 
 
 
In the present study we investigated a consanguineous Egyptian family with an 
autosomal recessive inherited epilepsy syndrome. Five of seven siblings are affected 
and present a phenotype with temporal lobe epilepsy, myoclonus and tremor. Via 
linkage analysis and exome sequencing we report a one basepair deletion in exon 6 
of the CNTN2 gene (c.503_503delG) in a homozygous state in all affected siblings 
and in a heterozygous state in the two healthy parents. The result of this deletion is a 
frameshift which consequently leads to an impairment or loss of enzyme function, 
due to change in structure of the protein and therefore may be considered to be a 
loss of function mutation.  
 
CNTN2, alternatively named TAG-1 (Transient Axonal Glycoprotein-1), is a neuronal 
cell adhesion molecule (CAM) which belongs to the contactin family of the 
immunoglobulin superfamily (IgSF). CNTN2 comprises six N-terminal 
Immunoglobulin (Ig)-like and four Fibronectin type III domains and is attached to the 
cell membrane by a glycosylphosphatidylinositol anchor (Furley, et al., 1990) 
(Figure10). The protein is transiently expressed in axons during development of the 
central and peripheral nervous system and in myelinating glia cells as an anchored 
form as well as a released form (Karagogeos, 2003; Poliak and Peles, 2003). It is 
expressed in several types of neurons inclusively in adult neurons of the dorsal root 
ganglia and their projections and in spinal motor neurons (Dodd et al., 1988; Traka 
et al., 2002 and 2003). CNTN2 interacts with a number of different binding partners 
and may play an important role in the initial stage of axon outgrowth and in 
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interaction between developing neurons. Further, CNTN2 is implicated in axon-glia 
interactions as it takes part in the organization of axonal subdomains at the node of 
Ranvier of myelinating fibers. The myelin sheath is structured in segments separated 
by the nodes of Ranvier, a myelin free region. The nodes are characterized by a high 
concentration of Na+ channels which are essential for the generation of the action 
potential during saltatory conduction (Waxman and Ritchie, 1993). Next to the node 
sits the paranodal junction formed by terminal cytoplasmic loops of the myelin onto 
the axolemma. The region adjacent to the paranodes is designated as the 
juxtaparanodes (Figure 11a). The juxtaparanode is enriched with shaker-type Kv1 
channels. These channels build a complex with the Caspr2 protein which 
subsequently forms a complex with CNTN2. CNTN2 is required for the 
juxtaparanodal clustering of Caspr2 and K+ channels (Poliak et al., 2003; Traka et 
al., 2003). In CNTN2 deficient mice (95% homology between human and rat 
homologues at the amino acid sequence level) axonal Caspr2 did not accumulate at 
juxtaparanodes and the normal enrichment of shaker-type K+ channels in these 
regions was severely disrupted (Traka et al., 2003). A model for this molecular 
interaction at the juxtaparanodal region suggests a complex consisting of a glial 
CNTN2 molecule and the axonal Caspr2 forming a heterodimer through the trans 
binding of CNTN2 with itself. This suggests that axon-glia interactions mediated by 
these proteins allow myelinating glia cells to organize ion channels such as Kv1.1 
and Kv1.2 in the underlying axonal membrane (Poliak et al., 2003; Traka et al., 
2003) (Figure 11b). So far, the role of the juxtaparanodal K+ channels is not 
completely understood. It is hypothesized that K+ channels act as an active damper 
of re-entrant excitation (Vabenick et al., 1999) which requires a high spatial 
clustering of K+ channels near the node and they maintain the resting potential for 
the entire nerve (Chiu and Ritchie, 1984). Although the K+ channel clustering was 
abolished in CNTN2 and Caspr2 deficient mice, the total content of K+ channels 
remained constant and the myelin-concealed K+ channels maintained the internodal 
resting potential (Poliak et al., 2003; Traka et al., 2003). According to these two 
studies, no gross morphological abnormalities of the central nervous system of 
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CNTN2 and Caspr2 deficient mice compared with the wild type were reported and 
no change in the excitability of myelinated nerves occurred. Nevertheless, in a 
previous study, mice lacking Kv1.1 and Kv1.2 exhibited increased seizure 
susceptibility and hyperexcitability in axons and Kv1.2 knock-out mice additionally 
showed myoclonus and tremor (Brew et al., 2007). Moreover, Fukamauchi et al., 
reported spontaneous epileptic seizures in CNTN2 deficient mice (Fukamauchi et al., 
2001). In 2006 Strauss et al. described a recessive symptomatic focal epilepsy in 
Older Amish People caused by a single base deletion in the CASPR2 gene. Brain 
samples of these patients showed an altered expression of Kv1.1 and Nav1.2 
channels (Strauss et al., 2006).  
 
Considering these findings, CNTN2 ranks highly among candidate genes for 
epilepsy. Thus, we subsequently performed capillary sequencing in TLE patients to 
investigate the contribution of the CNTN2 gene to the temporal lobe epilepsy 
phenotype in general. Overall, we did not find any homozygous mutation. The 
screening of all coding exons revealed heterozygous variants only. Assuming a 
recessive trait and considering the fact that the parents, heterozygous for the 
c.503_503delG mutation, presented no clinical symptoms of epilepsy at the time of 
examination, we cannot prove pathogenicity of these variants in our TLE patients. 
Thus, there is no indication that heterozygous variations influence the disease 
susceptibility. 
The `gold standard` in proving the pathogenicity of a given high risk variant is 
segregation in the family. However, as family history is often not available, this proof 
cannot be applied. In silico predictions of pathogenicity, such as calculated by 
PolyPhen, have to be considered with caution. Past studies have frequently shown 
that genetically proven mutations were predicted to be benign by PolyPhen and 
variations, irrelevant for the disease, were predicted to be probably damaging. The 
predictions are based on evolutionary conservation and theoretical assumptions of 
the 3 dimensional structure of a protein. To find out the relevance of a candidate 
gene in a given disease population it has become standard to screen in a first step 
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many patients for the whole gene (all exons), and in a second step, to genotype the 
found variants in a matched control population. Lack of occurrence of a variant in 
the control group is usually taken as a supportive argument for pathogenicity. The 
genome of any individual carries many thousands of private or very rare missense 
variants which do not obviously influence the phenotype of this person. It is therefore 
a matter of statistical chance that such variants are found in a given gene when 
screening hundreds of samples. Thus, a more reliable approach is to screen the 
whole gene in the same number of patients and control individuals. If the frequency 
of variants is then found to be higher in the patient group, it might be more likely to 
take this as a supportive argument for pathogenicity. We have evaluated the 
frequency of variants in the CNTN2 gene from the exome sequencing data of 72 
non epileptic patients. We have found four rare nonsynonmous coding variants in 72 
exome data, and seven in our 189 TLE patients. The identical frequency of rare 
variants in the patients and the control group indicates that CNTN2 is not likely to be 
a major contributor for the TLE phenotype in general.  
 
Nevertheless, we cannot preclude compound heterozygous mutations completely (the 
condition of having two heterogeneous recessive alleles causing the disease) as we 
did not screen the intronic and regulatory regions of the CNTN2 genes. Digenic 
inheritance (the disease is caused by an interaction of two gene-defects) cannot be 
excluded too. We did not screen any other genes, which may contain a second 
variant contributing in combination with the heterozygous CNTN2 variation to the 
TLE phenotype. According to the parents’ heterozygous state, regarding the 
c.503_503delG mutation, we know that in this case haploinsufficiency (a single copy 
of the normal gene is not capable of providing sufficient protein product as to assure 
normal function) of the CNTN2 protein does not underlie epilepsy. However, we 
cannot exclude the possibility of a dominant negative effect (heterozygous mutation 
that results in an altered gene product that acts antagonistically to the wilde-type 
allele) or loss of function (mutation that results in an impaired or abolished function 
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of the protein) in some of the other found heterozygous variations and thus, being 
possibly pathogenic. 
 
The remarkable phenotype of the Egyptian family and the limited comparability with 
our tested sample of TLE patients is further constricting our results. The phenotype of 
the Egyptian family consisting of an adolescent onset epilepsy syndrome with obvious 
temporal lobe features, myoclonus and tremor could most probably be arranged 
with a rare syndrome called familial cortical myoclonic tremor with epilepsy (FCMTE, 
BAFME, FAME) (van Rootselaar et al., 2005). However, these patients start with 
generalized tonic clonic seizures in adulthood, exhibit also myoclonus and tremor, 
but there are no definite references for temporal lobe epilepsy as in our case. 
Furthermore, contrary to our family, most of these families show an autosomal 
dominant trait. Three loci on chromosome 2p, 8q and 5q are described for this 
syndrome to date, but a causing gene has not yet been identified (Mikami et al., 
1999, Guerrini et al., 2001, Laubage et al., 2002, De Falco et al., 2003, Striano et 
al., 2004, Depienne et al., 2010).  
It cannot be ruled out that the c.503-503del G mutation, obviously disease causing 
in the described Egyptian family, could be unique to this family. Therefore it remains 
to be seen whether mutations affecting CNTN2 will be identified as causes of 
temporal lobe epilepsy in other populations.  
Nevertheless, the crucial role of CNTN2 in neuronal excitability makes this gene a 
perfect candidate for epilepsy. Future studies will show the significance of this new 
identified gene. 
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Figure 10: Schematic representation of CNTN2 protein. 
The protein comprises 6 N-terminal Ig-like and 4 Fibronectin type III domains. 
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Figure 11: Localization of CNTN2 under the myelin sheath. 
(a) Differentiation of the axonal membrane into nodes, paranodal junction, juxtaparanode and 
internodal region. (b) Axonal CNTN2 (TAG-1) formes a complex with Caspr2 and undergoes a 
homophilic binding with a glial CNTN2 (TAG-1) molecule at the juxtaparanodal region. Caspr2 in 
turns interacts with voltage gated K+ channels embedded in the membrane. (c) In CNTN2-deficient 
mice (CNTN2-/-) clustering of K+ channels at the juxtaparanode is altered and channels dissipated 
into the internode. 
Reprinted from “The local differentiation of myelinated axons at the Nodes of Ranvier.” by Poliak, S. 
and Peles, E. 2003. Nature Review. 4, p968 
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6 Appendix 
 
 
Figure 12: Nucleotide and amino acid sequence of the CNTN2 gene uc001hbr.1. 
Rare nonsynonymous coding variations identified by capillary sequencing are indicated in yellow. The 
c.503_503delG mutation of the Egyptian family is indicated in red.  
 
                   10        20        30        40        50        60         
          ----:----|----:----|----:----|----:----|----:----|----:----| 
        1 ATGGGGACAGCCACCAGGAGGAAGCCACACCTGCTGCTGGTAGCTGCTGTGGCCCTTGTC 60 
        1 M  G  T  A  T  R  R  K  P  H  L  L  L  V  A  A  V  A  L  V   20 
 
                   70        80        90        100       110       120        
          ----:----|----:----|----:----|----:----|----:----|----:----| 
       61 TCCTCTTCAGCTTGGAGTTCAGCCCTGGGATCCCAAACCACCTTCGGGCCTGTCTTTGAA 120 
       21 S  S  S  A  W  S  S  A  L  G  S  Q  T  T  F  G  P  V  F  E   40 
                   || 
                   exon2/exon3 
 
                   130       140       150       160       170       180        
          ----:----|----:----|----:----|----:----|----:----|----:----| 
      121 GACCAGCCCCTCAGTGTGCTATTCCCAGAGGAGTCCACGGAGGAGCAGGTGTTGCTGNCA 180 
       41 D  Q  P  L  S  V  L  F  P  E  E  S  T  E  E  Q  V  L  L  X   60 
 
                   190       200       210       220       230       240        
          ----:----|----:----|----:----|----:----|----:----|----:----| 
      181 TGCCGCGCCCGGGCCAGCCCTCCAGCCACCTATCGGTGGAAGATGAATGGTACCGAGATG 240 
       61 C  R  A  R  A  S  P  P  A  T  Y  R  W  K  M  N  G  T  E  M   80 
                                            || 
                                            exon3/exon4 
 
                   250       260       270       280       290       300        
          ----:----|----:----|----:----|----:----|----:----|----:----| 
      241 AAGCTGGAGCCAGGTTCCCGTCACCAGCTGGTGGGGGGCAACCTGGTCATCATGAANCCC 300 
       81 K  L  E  P  G  S  R  H  Q  L  V  G  G  N  L  V  I  M  X  P   100 
 
                   310       320       330       340       350       360        
          ----:----|----:----|----:----|----:----|----:----|----:----| 
      301 ACCAAGGCACAGGATGCCGGGGTCTACCAGTGCCTGGCCTCCAACCCAGTGGGCACCGTT 360 
      101 T  K  A  Q  D  A  G  V  Y  Q  C  L  A  S  N  P  V  G  T  V   120 
 
                   370       380       390       400       410       420        
          ----:----|----:----|----:----|----:----|----:----|----:----| 
      361 GTCAGCAGGGAGGCCATCCTCCGCTTCGGCTTTCTGCAGGAATTCTCCAAGGAGGAGCGA 420 
      121 V  S  R  E  A  I  L  R  F  G  F  L  Q  E  F  S  K  E  E  R   140 
                                        || 
                                        exon4/exon5 
 
                   430       440       450       460       470       480        
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          ----:----|----:----|----:----|----:----|----:----|----:----| 
      421 GACCCAGTGAAANCTCATGAAGGCTGGGGGGTGATGTTGCCCTGTAACCCACCTGCCCAC 480 
      141 D  P  V  K  X  H  E  G  W  G  V  M  L  P  C  N  P  P  A  H   160 
 
                   490       500       510       520       530       540        
          ----:----|----:----|----:----|----:----|----:----|----:----| 
      481 TACCCAGGCTTGTCCTACCGCTGGCTCCTCAACGAGTTCCCCAACTTCATCCCGACGGAC 540 
      161 Y  P  G  L  S  Y  R  W  L  L  N  E  F  P  N  F  I  P  T  D   180 
                || 
                exon5/exon6 
 
                   550       560       570       580       590       600        
          ----:----|----:----|----:----|----:----|----:----|----:----| 
      541 GGGCGTCACTTCGTGTCCCAGACCACAGGGAACCTGTACATTGCCCGAACCAATGCCTCA 600 
      181 G  R  H  F  V  S  Q  T  T  G  N  L  Y  I  A  R  T  N  A  S   200 
 
                   610       620       630       640       650       660        
          ----:----|----:----|----:----|----:----|----:----|----:----| 
      601 GACCTGGGCAACTACTCCTGTTTGGCCACCAGCCACATGGACTTCTCCACCAAGAGCGTC 660 
      201 D  L  G  N  Y  S  C  L  A  T  S  H  M  D  F  S  T  K  S  V   220 
 
                   670       680       690       700       710       720        
          ----:----|----:----|----:----|----:----|----:----|----:----| 
      661 TTCAGCAAGTTTGCTCAGCTCAACCTGGCTGCTGAAGATACCCNGCTCTTTGCACCCAGC 720 
      221 F  S  K  F  A  Q  L  N  L  A  A  E  D  T  X  L  F  A  P  S   240 
                                              || 
                                              exon6/exon7 
 
                   730       740       750       760       770       780        
          ----:----|----:----|----:----|----:----|----:----|----:----| 
      721 ATCAAGGCCCGGTTCCCAGCAGAGACCTATGCACTGGTGGGGCAGCAGGTCACCCTGGAG 780 
      241 I  K  A  R  F  P  A  E  T  Y  A  L  V  G  Q  Q  V  T  L  E   260 
 
                   790       800       810       820       830       840        
          ----:----|----:----|----:----|----:----|----:----|----:----| 
      781 TGCTTCGCCTTTGGGAACCCTGTCCCCCGGATCAAGTGGCGCAAAGTGGACGGCTCCCTG 840 
      261 C  F  A  F  G  N  P  V  P  R  I  K  W  R  K  V  D  G  S  L   280 
                          || 
                          exon7/exon8 
 
                   850       860       870       880       890       900        
          ----:----|----:----|----:----|----:----|----:----|----:----| 
      841 TCCCCGCAGTGGACCACAGCTGAGCCCACCCTGCAGATCCCCAGCGTCAGCTTNGAGGAT 900 
      281 S  P  Q  W  T  T  A  E  P  T  L  Q  I  P  S  V  S  X  E  D   300 
 
                   910       920       930       940       950       960        
          ----:----|----:----|----:----|----:----|----:----|----:----| 
      901 GAGGGCACCTACGAGTGTGAGGCGGAGAACTCCAAGGGCCGAGACACCGTGCAGGGCCGC 960 
      301 E  G  T  Y  E  C  E  A  E  N  S  K  G  R  D  T  V  Q  G  R   320 
 
                   970       980       990       1000      1010      1020       
          ----:----|----:----|----:----|----:----|----:----|----:----| 
      961 ATCATCGTGCAGGCTCAGCCTGAGTGGCTAAAAGTGATCTCGGACACAGAGGCTGACATT 1020 
      321 I  I  V  Q  A  Q  P  E  W  L  K  V  I  S  D  T  E  A  D  I   340 
                      || 
                      exon8/exon9 
 
                   1030      1040      1050      1060      1070      1080       
          ----:----|----:----|----:----|----:----|----:----|----:----| 
     1021 GGCTCCAACCTGCGTTGGGGCTGTGCAGCCGCCGGCAAGCCCCGGCCTACAGTGCGCTGG 1080 
      341 G  S  N  L  R  W  G  C  A  A  A  G  K  P  R  P  T  V  R  W   360 
 
                   1090      1100      1110      1120      1130      1140       
          ----:----|----:----|----:----|----:----|----:----|----:----| 
  60  
     1081 CTGCGGAACGGGGAGCNTCTGGCCTCCCAGAACCGGGTGGAGGTGTTGGCTGGGGACCTG 1140 
      361 L  R  N  G  E  X  L  A  S  Q  N  R  V  E  V  L  A  G  D  L   380 
                                       || 
                                       exon9/exon10 
 
                   1150      1160      1170      1180      1190      1200       
          ----:----|----:----|----:----|----:----|----:----|----:----| 
     1141 CGGTTCTCCAAGCTGAGCCTGGAAGACTCGGGCATGTACCAGTGTGTGGCAGAGAATAAG 1200 
      381 R  F  S  K  L  S  L  E  D  S  G  M  Y  Q  C  V  A  E  N  K   400 
 
                   1210      1220      1230      1240      1250      1260       
          ----:----|----:----|----:----|----:----|----:----|----:----| 
     1201 CACGGTACCATCTACGCCAGCGCCGAGCTAGCCGTGCAAGCACTCGCCCCTGACTTCAGG 1260 
      401 H  G  T  I  Y  A  S  A  E  L  A  V  Q  A  L  A  P  D  F  R   420 
                                                 || 
                                                 exon10/exon11 
 
                   1270      1280      1290      1300      1310      1320       
          ----:----|----:----|----:----|----:----|----:----|----:----| 
     1261 CTGAATCCCGTGAGGCGTCTGATCCCCGCGGCCCGCGGGGGAGAGATCCTTATCCCCTGC 1320 
      421 L  N  P  V  R  R  L  I  P  A  A  R  G  G  E  I  L  I  P  C   440 
 
                   1330      1340      1350      1360      1370      1380       
          ----:----|----:----|----:----|----:----|----:----|----:----| 
     1321 CAGCCCCGGGCAGCTCCAAAGGCCGTGGTGCTCTGGAGCAAAGGCACGGAGATTTTGGTC 1380 
      441 Q  P  R  A  A  P  K  A  V  V  L  W  S  K  G  T  E  I  L  V   460 
 
                   1390      1400      1410      1420      1430      1440       
          ----:----|----:----|----:----|----:----|----:----|----:----| 
     1381 AACAGCAGCAGAGTGACTGTAACTCCAGATGGCACCTTGATCATAAGAAACATCAGCCGG 1440 
      461 N  S  S  R  V  T  V  T  P  D  G  T  L  I  I  R  N  I  S  R   480 
                    || 
                    exon11/exon12 
 
                   1450      1460      1470      1480      1490      1500       
          ----:----|----:----|----:----|----:----|----:----|----:----| 
     1441 TCAGATGAAGGCAAATACACCTGCTTTGCTGAGAACTTCATGGGCAAAGCCAACAGCACT 1500 
      481 S  D  E  G  K  Y  T  C  F  A  E  N  F  M  G  K  A  N  S  T   500 
 
                   1510      1520      1530      1540      1550      1560       
          ----:----|----:----|----:----|----:----|----:----|----:----| 
     1501 GGAATCCTATCTGTGCGAGATGCAACCAAAATCACTCTAGCCCCCTCAAGTGCCGACATC 1560 
      501 G  I  L  S  V  R  D  A  T  K  I  T  L  A  P  S  S  A  D  I   520 
                            || 
                            exon12/exon13 
 
                   1570      1580      1590      1600      1610      1620       
          ----:----|----:----|----:----|----:----|----:----|----:----| 
     1561 AACTTGGGTGACAACCTGACCCTACAGTGCCATGCCTCCCACGACCCCACCATGGACCTC 1620 
      521 N  L  G  D  N  L  T  L  Q  C  H  A  S  H  D  P  T  M  D  L   540 
 
                   1630      1640      1650      1660      1670      1680       
          ----:----|----:----|----:----|----:----|----:----|----:----| 
     1621 ACCTTCACCTGGACCCTGGACGACTTCCCCATCGACTTTGATAAGCCTGGAGGGCACTAC 1680 
      541 T  F  T  W  T  L  D  D  F  P  I  D  F  D  K  P  G  G  H  Y   560 
 
                   1690      1700      1710      1720      1730      1740       
          ----:----|----:----|----:----|----:----|----:----|----:----| 
     1681 CGGAGAACTAATGTGAAGGAGACCATTGGGGATCTGACCATCCTGAACGCCCAGCTGCGC 1740 
      561 R  R  T  N  V  K  E  T  I  G  D  L  T  I  L  N  A  Q  L  R   580 
                        || 
                        exon13/exon14 
 
                   1750      1760      1770      1780      1790      1800       
  61  
          ----:----|----:----|----:----|----:----|----:----|----:----| 
     1741 CATGGGGGGAAGTACACGTGCATGGCCCAGACGGTGGTGGACAGCGCGTCCAAGGAGGCC 1800 
      581 H  G  G  K  Y  T  C  M  A  Q  T  V  V  D  S  A  S  K  E  A   600 
 
                   1810      1820      1830      1840      1850      1860       
          ----:----|----:----|----:----|----:----|----:----|----:----| 
     1801 ACAGTCCTGGTCCGAGGTCCGCCANGTCCCCCAGGAGGTGTGGTGGTGAGGGACATTGGC 1860 
      601 T  V  L  V  R  G  P  P  X  P  P  G  G  V  V  V  R  D  I  G   620 
                         || 
                         exon14/exon15 
 
                   1870      1880      1890      1900      1910      1920       
          ----:----|----:----|----:----|----:----|----:----|----:----| 
     1861 GACACCACCATCCAGCTCAGCTGGAGCCGTGGCTTCGACAACCACAGCCCCATCGCTAAG 1920 
      621 D  T  T  I  Q  L  S  W  S  R  G  F  D  N  H  S  P  I  A  K   640 
 
                   1930      1940      1950      1960      1970      1980       
          ----:----|----:----|----:----|----:----|----:----|----:----| 
     1921 TACACCCTGCAAGCTCGCACTCCACCTGCAGGGAAGTGGAAGCAGGTTNGGACCNATCCT 1980 
      641 Y  T  L  Q  A  R  T  P  P  A  G  K  W  K  Q  V  X  T  X  P   660 
                                                                || 
                                                              exon15/exon16 
 
                   1990      2000      2010      2020      2030      2040       
          ----:----|----:----|----:----|----:----|----:----|----:----| 
     1981 GCAAACATCGAGGGCAATGCCGAGACTGCACAGGTGCTGGGCCTCACCCCCTGGATGGAC 2040 
      661 A  N  I  E  G  N  A  E  T  A  Q  V  L  G  L  T  P  W  M  D   680 
 
                   2050      2060      2070      2080      2090      2100       
          ----:----|----:----|----:----|----:----|----:----|----:----| 
     2041 TATGAGTTCCGGGTCATAGCCAGCAACATTCTGGGCACTGGGGAGCCTAGTGGGCCCTCC 2100 
      681 Y  E  F  R  V  I  A  S  N  I  L  G  T  G  E  P  S  G  P  S   700 
 
                   2110      2120      2130      2140      2150      2160       
          ----:----|----:----|----:----|----:----|----:----|----:----| 
     2101 AGCAAAATCCGGACCAGGGAAGCAGCCCCCTCGGTGGCACCCTCAGGACTCAGCGGAGGA 2160 
      701 S  K  I  R  T  R  E  A  A  P  S  V  A  P  S  G  L  S  G  G   720 
                                  || 
                                  exon16/exon17 
 
                   2170      2180      2190      2200      2210      2220       
          ----:----|----:----|----:----|----:----|----:----|----:----| 
     2161 GGTGGAGCCCCCGGAGAGCTCATCGTCAACTGGACGCCCATGTCACGGGAGTACCAGAAC 2220 
      721 G  G  A  P  G  E  L  I  V  N  W  T  P  M  S  R  E  Y  Q  N   740 
                                             || 
                                             exon17/exon18 
 
                   2230      2240      2250      2260      2270      2280       
          ----:----|----:----|----:----|----:----|----:----|----:----| 
     2221 GGAGACGGCTTCGGCTACCTGCTGTCCTTCCGCAGGCAGGGCAGCACTCACTGGCAGACC 2280 
      741 G  D  G  F  G  Y  L  L  S  F  R  R  Q  G  S  T  H  W  Q  T   760 
 
                   2290      2300      2310      2320      2330      2340       
          ----:----|----:----|----:----|----:----|----:----|----:----| 
     2281 GCCCGGGTGCCTGGCGCCGATGCCCAGTACTTTGTCTACAGCAACGAGAGCGTCCGGCCC 2340 
      761 A  R  V  P  G  A  D  A  Q  Y  F  V  Y  S  N  E  S  V  R  P   780 
 
                   2350      2360      2370      2380      2390      2400       
          ----:----|----:----|----:----|----:----|----:----|----:----| 
     2341 TACACGCCCTTTGAGGTCAAGATCCGCAGCTACAACCGCCGCGGGGATGGGCCCGAGAGC 2400 
      781 Y  T  P  F  E  V  K  I  R  S  Y  N  R  R  G  D  G  P  E  S   800 
 
                   2410      2420      2430      2440      2450      2460       
          ----:----|----:----|----:----|----:----|----:----|----:----| 
  62  
     2401 CTCACTGCACTCGTGTACTCAGCTGAGGAAGAGCCCAGGGTGGCCCCTACCAAGGTGTGG 2460 
      801 L  T  A  L  V  Y  S  A  E  E  E  P  R  V  A  P  T  K  V  W   820 
                                        || 
                                        exon18/exon19 
 
                   2470      2480      2490      2500      2510      2520       
          ----:----|----:----|----:----|----:----|----:----|----:----| 
     2461 GCCAAAGGGGTCTCATCCTCAGAGATGAACGTGACCTGGGAACCCGTGCAGCAGGACATG 2520 
      821 A  K  G  V  S  S  S  E  M  N  V  T  W  E  P  V  Q  Q  D  M   840 
 
                   2530      2540      2550      2560      2570      2580       
          ----:----|----:----|----:----|----:----|----:----|----:----| 
     2521 AATGGTATCCTCCTGGGGTATGAGATCCGCTACTGGAAAGCTNGGGACAAAGAAGCAGCT 2580 
      841 N  G  I  L  L  G  Y  E  I  R  Y  W  K  A  X  D  K  E  A  A   860 
                                 || 
                                 exon19/exon20 
 
                   2590      2600      2610      2620      2630      2640       
          ----:----|----:----|----:----|----:----|----:----|----:----| 
     2581 GCGGACCGAGTGAGGACAGCAGGGCTGGACACCANTGCCCGAGTCAGNGGCCTGCATCCC 2640 
      861 A  D  R  V  R  T  A  G  L  D  T  X  A  R  V  X  G  L  H  P   880 
 
                   2650      2660      2670      2680      2690      2700       
          ----:----|----:----|----:----|----:----|----:----|----:----| 
     2641 AACACCAAGTACCATGTGACCGTGAGGGCCTACAACCGGGCTGGCACTGGGCCTGCCAGC 2700 
      881 N  T  K  Y  H  V  T  V  R  A  Y  N  R  A  G  T  G  P  A  S   900 
 
                   2710      2720      2730      2740      2750      2760       
          ----:----|----:----|----:----|----:----|----:----|----:----| 
     2701 CCTTCTGCCAACGCCACGACCATGAAGCCCCCTCCGCGGCGACCTCCTGGCAACATCTCC 2760 
      901 P  S  A  N  A  T  T  M  K  P  P  P  R  R  P  P  G  N  I  S   920 
                                        || 
                                        exon20/exon21 
 
                   2770      2780      2790      2800      2810      2820       
          ----:----|----:----|----:----|----:----|----:----|----:----| 
     2761 TGGACTTTCTCAAGCTCTAGTCTTAGCATTAAGTGGGACCCTGTGGTCCCTTTCCGAAAT 2820 
      921 W  T  F  S  S  S  S  L  S  I  K  W  D  P  V  V  P  F  R  N   940 
 
                   2830      2840      2850      2860      2870      2880       
          ----:----|----:----|----:----|----:----|----:----|----:----| 
     2821 GAGTCTGCAGTCACCGGCTATAAGATGCTGTACCAGAATGACTTACACCTGACTCCCACG 2880 
      941 E  S  A  V  T  G  Y  K  M  L  Y  Q  N  D  L  H  L  T  P  T   960 
                                 || 
                                 exon21/exon22 
 
                   2890      2900      2910      2920      2930      2940       
          ----:----|----:----|----:----|----:----|----:----|----:----| 
     2881 CTCCANCTCACCGGCAAGAACTGGATAGAAATCCCAGTGCCTGAAGACATTGGCCATGCC 2940 
      961 L  X  L  T  G  K  N  W  I  E  I  P  V  P  E  D  I  G  H  A   980 
 
                   2950      2960      2970      2980      2990      3000       
          ----:----|----:----|----:----|----:----|----:----|----:----| 
     2941 CTGGTACAAATTCGGACCACAGGGCCCGGAGGGGATGGGATCCCTGCAGAAGTCCACATC 3000 
      981 L  V  Q  I  R  T  T  G  P  G  G  D  G  I  P  A  E  V  H  I   1000 
 
                   3010      3020      3030      3040      3050      3060       
          ----:----|----:----|----:----|----:----|----:----|----:----| 
     3001 GTGAGGAATGGAGGCACAAGCATGATGGTGGAGAACATGGCAGTCCGCCCAGCACCACAC 3060 
     1001 V  R  N  G  G  T  S  M  M  V  E  N  M  A  V  R  P  A  P  H   1020 
                      || 
                      exon22/exon23 
 
                   3070      3080      3090      3100      3110      3120       
  63  
          ----:----|----:----|----:----|----:----|----:----|----:----| 
     3061 CCTGGCACCNTCATTTCCCACTCCGTGGCGATGCTGATCCTCATAGGCTCCCTGGAGCTC 3120 
     1021 P  G  T  X  I  S  H  S  V  A  M  L  I  L  I  G  S  L  E  L   1040 
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